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Human papillomavirus (HPV) is known to be the cause of anogenital and oropharyngeal cancers as 
well as genital and common warts. There are currently three prophylactic virus-like particle (VLP) 
based vaccines. These vaccines, however, do not offer protection against all HPV strains and cannot 
act therapeutically and so further vaccine development is still needed. The burden of HPV is also 
highest in low-income countries for which the vaccine costs are still quite high, and therefore 
alternative methods of vaccine production and testing are needed. HPV pseudovirions (PsVs) are 
synthetic viral particles that are made up of the L1 major and L2 minor HPV capsid proteins and 
encapsidate up to 8Kb of pseudogenome DNA without the need of an encapsidation signal. HPV PsVs 
are used to test neutralising antibodies elicited by vaccines, for studying the virus life cycle, and 
potentially for delivery of therapeutic DNA vaccines. HPV PsVs are typically produced in mammalian 
cells; however, it has recently been shown that HPV PsVs can be produced in plants, a potentially safer, 
cheaper and more easily scalable means of production. While, a current problem with plant HPV PsV 
production is low yields, research has shown that using pseudogenome DNAs between 5-7Kb 
increases yields of papillomavirus PsVs in mammalian cells. Therefore, the objective of this study was 
to determine the optimal pseudogenome size for encapsidation by plant produced PsVs, in order to 
increase the amount of PsVs in a sample as opposed to VLPs.  
 
Pseudogenome constructs encoding Enhanced Green Fluorescent Protein (EGFP )and ranging in size 
from 4.8Kb – 7.8kb were cloned into a geminivirus-derived replicating vector, transformed into 
Agrobacterium tumefaciens and then infiltrated into Nicotiana benthamiana along with plant 
expression vectors encoding the HPV 35 L1 and L2 capsid proteins. Particles were purified by iodixanol 
density gradient ultracentrifugation and the 27% and 33% fractions of this gradient analysed. 
Transmission electron microscopy (TEM) was used to confirm particle assembly and L1 expression was 
quantified by ELISA. Particles were disrupted with proteinase K and quantitative PCR was used to 
quantify the encapsidated DNA. Ratios of encapsidated DNA to L1 capsid protein were calculated for 
each of the PsV samples with different sized pseudogenomes, to account for batch-to-batch variation 
and as an approximation of which size pseudogenome is better encapsidated. Infective ability of the 
particles was analysed by incubating the PsVs onto HEK293TT cells and then checking for DNA delivery 
and protein expression by measuring EGFP expression by Western blots. The results showed that PsVs 
are found predominantly in the 27% fraction of the iodixanol gradient whereas the 33% fraction of the 
gradient appears to only contain VLPs.  The data also indicated that the smaller pseudogenomes, were 
packaged more efficiently into PsVs as higher concentrations of encapsidated DNA and higher levels 




larger 5.8 - 7.8Kb pseudogenomes were used. Thus, the results showed that smaller pseudogenomes, 
around 4.8Kb, should be used for the plant production of HPV 35 PsVs as they are better packaged 





Chapter 1: Literature review 
 
1.1.  Introduction 
In 2015, the World Health Organization (WHO) estimated cancer to be one of the top two leading 
causes of death in persons younger than 70 years old in 91 out of 172 countries. Human papillomavirus 
(HPV) is a sexually transmitted virus that was estimated to be the most common sexually transmitted 
disease in the USA (Hamborsky et al., 2015). HPV causes genital and common warts, as well as 
anogenital and oropharyngeal cancers,  with 5% of all human cancers being caused by HPV (De Martel 
et al., 2012). HPV affects both men and women with more women developing cancers, particularly 
cervical cancer, and warts than men (Bray et al., 2018). High-risk (HR) HPV strains like HPV 16 and 18 
often cause anogenital and oropharyngeal cancers whereas low-risk (LR) strains, such as HPV   6 and 
11, often result in genital and common warts.  
1.1.1. Human papillomavirus (HPV) statistics and demographics  
Cervical cancer is the most common HPV induced cancer and is the second most frequent cancer in 
women aged 15 to 44 years (Bruni et al., 2015a, Bruni et al., 2015b, Ferlay et al., 2013). In 2018, it was 
estimated that 570 000 cases of cervical cancer arose annually globally, of which 311 000 were fatal 
(Bray et al., 2018). Furthermore, studies show that low-income countries have the highest burden of 
incidences and fatalities, particularly in Southern, Western and Eastern Africa (Ferlay et al., 2013, Bray 
et al., 2018) whereas  high income countries are close to eradicating HPV, with North America, 
Australia/New Zealand, and Western Asia having 7-10 times lower incidence and mortality rates than 
developing countries, with Australia being close to completely eradicating HPV (Bralsford and 
Jamieson, 2019, Bray et al., 2018, Serrano et al., 2018). Lower incidence and mortality in high-income 
countries can be attributed to better sex education, better genital hygiene and most importantly 
better accessibility and affordability of healthcare including HPV screening and vaccination 
programmes (Bray et al., 2005a, Bray et al., 2018, Bray et al., 2005b, Bray et al., 2013, W.H.O., 2005).  
1.1.2.  HPV mitigation  
HPV involvement in female genital lesions is currently screened for by Pap smear and PCR genotyping, 
with surgery being the main treatment for HPV related cancers and warts. There are three prophylactic 
vaccines on the market. These vaccines are L1 virus-like particle (VLP) based vaccines. VLPs are 
synthetic, non-replicative, self-assembling viral capsids that stimulate protective neutralising antibody 
responses. The first vaccine to be released was the Gardasil® quadrivalent vaccine, in 2006. This 
vaccine is licenced for use in both males and females and protects against the globally common HR 




strains, 6 and 11 which are known to cause genital warts. GlaxoSmithKline (GSK) then released 
Cervarix ® in 2007: this protects against HPV 16 and 18 and is currently only licenced for use in women. 
Finally, the Gardasil® nonavalent vaccine, first released in the USA in 2014, protects against HPV 6, 11, 
16, 18, 31, 33, 45, 52, 58 strains and is licenced for use in both males and females. These vaccines have 
been shown to be highly efficacious with the HPV incidence decreasing by 56% in the USA in the first 
four years following vaccine implementation (Markowitz et al., 2013).  
While great success has been achieved with these vaccines, they are, however, unable to function 
therapeutically and are therefore unable to treat already infected individuals, offer limited cross-
protectivity against non-vaccine strains, and finally, they are expensive (Schiller and Müller, 2015, 
Petrosky et al., 2015) which makes them less accessible to low income countries where incidence and 
mortality are between 20% (Africa) and 50% (Asia) (Bray et al., 2018, W.H.O., 2018). Furthermore, the 
prevalence of HPV strains varies geographically, with the vaccine strains being the most globally 
prevalent strains. There are other strains however, such as HPV 35 which is not included in any of the 
vaccines but is prevalent in Africa and not necessarily in other parts of the world (Smith et al., 2007, 
De Sanjose et al., 2010). Thus, more work is needed to broaden the spectrum of HPV prophylactic 
vaccines, develop therapeutic vaccines and decrease the cost of the vaccine production to increase 
affordability for low-income countries where the burden of HPV is the highest.   
 
1.2 HPV Characterisation 
HPV belongs to the Papillomaviridae family of viruses that are known to infect cutaneous and mucosal 
epithelia. There are 16 genera in the Papillomaviridae family, 5 of which, the α, β, γ, µ, and ν genera, 
are known as HPVs. To date, these 5 genera  contain over 207 different HPV types. These HPV types 
have been identified and separated into genera based on their L1 capsid protein gene sequence 
homology. The α HPVs are the largest genus, containing mostly mucosal infecting viruses, 40 of which 
infect the anogenital tract but only 15 of which are HR, oncogenic types (HPVs 16, 18, 31, 33, 35, 39, 
45, 51, 56, 58, 59, 68, 73, 82) (Stanley, 2010, Van Doorslaer et al., 2012, Van Doorslaer et al., 2016) . 
The β HPVs are the second largest group of HPVs, infecting cutaneous epithelia of patients who are 
immunosuppressed and patients with genomic mutations that cause epidermodysplasia verruciformis 
disease (Pass et al., 1977, Pfister, 2003). These β HPVs have also been known to be associated with 
non-melanoma squamous cell carcinomas when combined with UV, one of the most common cancers 






1.2.1.  HPV particle structure   
HPV is a double-stranded DNA (dsDNA) virus, with a circular 8Kb genome. The virion has a T=7 
icosahedral structure, composed mainly of the L1 major capsid protein (360 copies) with the L2 minor 
capsid proteins (12-72 copies) to form a 55nm particle (Conway and Meyers, 2009, Cerqueira and 
Schiller, 2017). To form an HPV capsid, L1 molecules bind to each other to form pentameric 
capsomeres.  These capsomeres bind to each other, via disulphide bridges, to form the T=7 icosahedral 
capsid (Fligge et al., 2001, Ishii et al., 2005, Wolf et al., 2010). Approximately one L2 molecule binds 
to one capsomere, resulting in a L1 capsid containing 12 L2 molecules (Buck et al., 2008). However, 
some research has shown that L2 can actually bind up to 72 molecules per capsid (Buck et al., 2008, 
Finnen et al., 2003, Pereira et al., 2009, Cardone et al., 2014). 
 
1.2.2. HPV genome structure 
The HPV genome is divided into three regions (Figure 1). The first region encodes the early expressed 
regulatory proteins, the second encodes the late expressed regulatory proteins and the third region 
contains non-coding regions/long control regions (LCR) that contain regulatory sequences for DNA 
replication and transcription (Harden and Munger, 2017).  The early expressed regulatory genes 
include the E1, E2, E4, E5, E6 and E7 genes and a E2^E8 fusion. These genes are responsible for DNA 
replication, transcription and carcinogenesis (Harden and Munger, 2017, Graham, 2017b, Brentjens 
et al., 2002, Münger and Howley, 2002). E1 and E2 are the first genes to be expressed. E1 is a helicase 
enzyme responsible for initiating replication of the DNA by binding to the origin of replication along 
with E2 to stabilise it (Bergvall et al., 2013). The E4 gene is located within the E2 gene and is expressed 
as an E2^E4 fusion protein which is involved in aiding viral release and spread in later stages (Doorbar, 
2013). The E5 protein is a transmembrane protein that facilitates the evasion of immune responses 
and apoptosis by activating epidermal growth factor (EGF) and Platelet-derived growth factor (PDGF) 
receptors (Dimaio and Petti, 2013). Finally, E6 and E7 are the oncogenes responsible for cancer 
formation after infection with HR HPVs. E6 targets the p53 tumour suppressor for degradation and E7 
targets retinoblastoma (Rb) tumour suppressor proteins for degradation and therefore, they are 
essential for carcinogenesis as they disrupt the cell cycle and cause genomic instability and ultimately 
carcinogenesis (Münger et al., 1989, Roman and Munger, 2013, Mittal and Banks, 2017). The HPV 
genome also encodes for the L1 major and the L2 minor capsid proteins (Figure 1) , however, these 
proteins are only expressed during the late stages of the HPV life cycle when the newly synthesised 





Figure 1: HPV genome structure. Three genome regions shown: Early region encoding DNA replication and 
transcription regulatory proteins as well as the E6 and E7 oncogenes, Late region encoding the capsid proteins 
and the Long control regions (arrows) containing the DNA replication and transcription regulatory sequences. 
Image drawn using Geneious version 2019.1 created by Biomatters, available from https://www.geneious.com, 
using the Human papillomavirus isolate KC8 complete genome (Accession JX413110) as a backbone. 
 
 
1.3. HPV Life Cycle 
 
1.3.1. HPV infectivity 
HPV infects through microabrasions in the skin and binds to heparin sulphate proteoglycan receptors 
(HSPGs) on either the basement membrane or the basal epithelial cells (Figure 2) (Johnson et al., 2009, 
Joyce et al., 1999, Kines et al., 2009). This binding causes a cyclophin-B-mediated conformational 




al., 2009, Day et al., 2008) which in turn allows for a conformational change in L1 to allow it to bind to 
a secondary receptor on the basal keratinocytes (Kines et al., 2009, Day et al., 2008, Day et al., 2010, 
Aksoy et al., 2017). The virus enters the cell via clathrin independent micropinocytosis (Digiuseppe et 
al., 2017b, Pyeon et al., 2009). Cyclin B then dissociates L1 from the L2/genome complex and 
sequesters it for degradation in the lysosome (Raff et al., 2013). L2 is responsible for trafficking the -
genome, within the endosome, through the trans-Golgi network and into the nucleus (Day et al., 1998, 
Wang and Roden, 2013), however, the viral genome can only enter the nucleus during mitosis (Pyeon 
et al., 2009). The L2 and genome then localise at nuclear domain 10 where transcription can take place 
(Day et al., 2004). Most HPV infections are able to be cleared by the immune system (Goodman et al., 
2008, Rosa et al., 2008), however, in the case of a compromised immune system and infection with 
an HR HPV, disease progression occurs (Zur Hausen, 2002). 
 
 
Figure 2: HPV viral life cycle. HPV enters through a microscopic cut in the skin and binds to heparin sulphate 
proteoglycan receptors on the basement membrane or the basal keratinocytes of the epithelia. This causes a 
conformational change and opens L2 up for furin cleavage. L2 is then able to bind a secondary receptor on the 
basal cells and enter the cell. The viral life cycle, DNA replication and gene expression, develops as cell 
differentiation and proliferation occurs. Infection of the basal cells and viral persistence in the basal cell layer 
progresses to viral genome amplification as the cells differentiate into suprabasal cells. Progression to viral 
assembly and maturation occurs when the suprabasal cells differentiate into the granular cells. Following 
differentiation of the granular cells into cornified cells, on the skin surface, the viral particles are released.  Image 
drawn in Microsoft Powerpoint ® with guidance from Graham et. al., 2017 and Harden and Munger 2017 
(Graham, 2017a, Harden and Munger, 2017).  
 
1.3.2.  HPV latent phase 
HPV requires actively dividing cells in order for new viruses to be generated and so the HPV viral life 
cycle is closely linked to the differentiation of the basal epithelial cells that they infect (Egawa et al., 
2015, Pyeon et al., 2009). In the basal layer of the cells, E2 acts as a linker between the viral episome 
and the host chromosome allowing it to be replicated with the host DNA, while also repressing 




by E1 and E2 binding to the origin of replication on the episome and this keeps the infection latent, 
potentially for decades (Maglennon et al., 2011). Low copy number maintenance ensures immune 
evasion (Westrich et al., 2017) and it also ensures that the genome is transferred into the new basal 
cells as they divide, thereby moving up through the layers of the epithelium (Peh et al., 2002, Oldak 
et al., 2004).  
 
1.3.3. HPV vegetative phase 
The vegetative stage is where the viral genome is amplified, and the rest of the early genes are 
expressed. Here, the E1 and E2 proteins regulate the expression of the E6 and E7 oncogenes, which 
bind the p53 and pRB tumour suppressors, respectively, and target them for degradation.  This causes 
disruptions in the cell cycle and the apoptotic process, causing the cells to continue replicating and 
accumulating mutations which ultimately lead to cancer (Münger et al., 1989, Roman and Munger, 
2013, Mittal and Banks, 2017). The HPV genome is known to often linearize and integrate into the 
host genome. This causes further genetic instability in the host genome and can disrupt the E2 gene 
and thereby inhibits the repression of E6 and E7 oncogene transcription (Doorbar et al., 2012) which 
causes upregulation of these oncogenes and thereby cancer progression.  
 
1.3.4. HPV late phase 
In the late phase of the viral life cycle the L1 major and L2 minor capsid proteins are expressed and 
the virus is assembled and released. L2 is the first to accumulate in the nucleus at the nuclear domain 
10 site (ND-10, also known as PML bodies) with the help of the Hsc70 chaperone protein (Day et al., 
1998, Florin et al., 2002, Becker et al., 2004). The L1 proteins assemble into capsomeres in the 
cytoplasm and then translocate into the nucleus with the help of karyopherin chaperones (Bird et al., 
2008, Merle et al., 1999, Nelson et al., 2002). Once in the nucleus the L1/L2 capsid can form and bind 
the genome to encapsidate it (Nelson et al., 2000, Mallon et al., 1987, Li et al., 1997). Once assembled, 
the virions mature in the oxidising environment of the granular layer, with the L1 disulphide bonds 
crosslinking and becoming more resistant to proteolysis (Conway and Meyers, 2009, Conway et al., 
2009, Cardone et al., 2014). The virus is then spread when the skin cells die naturally, and the nuclear 
membrane and cell walls break down.  
 
 
1.4. Synthetic HPVs 
HPV naturally infects and replicates in terminally differentiated basal keratinocytes (Barksdale and 




hindered the study of HPV particles and vaccine development (Conway and Meyers, 2009, Kang et al., 
2000). Therefore, different model systems had to be derived to propagate HPV particles. 
One of the first models used to generate HPV were xenografts. Xenografts are made by grafting 
infectious patient tissue onto immunodeficient mice. This results in the formation of a tumour from 
which the virus can be extracted (Christensen et al., 1997, Howett et al., 1990, Bonnez, 2005). The 
alternative to xenografts, are raft cultures, a 3T3 fibroblast matrix simulating the stratified nature of 
epithelia which enables researchers to mimic the viral life cycle throughout basal keratinocyte 
differentiation (Dollard et al., 1992, Meyers et al., 1992). However, these methods are both expensive 
and require highly specialised skills and so alternative ways of studying and producing HPV particles 
had to be developed. Thus, synthetic HPV particles - VLPs, virions and pseudovirions that can be 
produced in mammalian, insect or yeast cells, were developed.  
1.4.1. Virus-like-particles 
VLPs are synthetic, non-replicating viral particles that self-assemble and do not contain viral DNA. 
These particles have been used with much success in the current HPV vaccines inducing high titres of 
neutralising antibodies (Handisurya et al., 2016, Schiller and Lowy, 2018). Clinical trials and follow-up 
studies have found these L1 VLP-based vaccines to be safe and effective (Handisurya et al., 2016, 
Schiller and Lowy, 2018, Schiller et al., 2012), and resulting in no new HPV-16/18 infections 9 years 
after vaccination (Naud et al., 2014, Markowitz et al., 2013). The success of the HPV VLP vaccine can 
be attributed to a variety of characteristics associated with VLPs (Mohsen et al., 2017). The first reason 
for this is that VLPs are small (HPV = 55nm) and are able to diffuse through the pores of the lymph 
vessels, allowing them to be circulated throughout the body. Secondly, the repetitive structure of the 
VLP is also ideal for stimulation of the immune response by recognition by pathogen-associated 
receptors and it provides stable crosslinking to B-cell receptors which could explain the high levels of 
neutralising antibodies induced by these vaccines (Bachmann et al., 1997, Bachmann and Jennings, 
2010, Schiller and Lowy, 2018).  Furthermore, the innate immune system components are also 
multimeric in structure which makes for strong binding to the VLP and thereby increases the efficiency 
of opsonisation uptake by antigen presenting cells (Gomes et al., 2017).  Thus, the VLP vaccines are 
very effective.  
There is, however, still room for improvement on these vaccines. The first problem is that they are 
very expensive to produce and deliver (cold chain) and low-income countries struggle to afford them, 
even with funding from the Global Alliance for Vaccines and Immunisation (GAVI) keeping the cost 
down to 5 USD/dose (Rep, 2013).  Secondly, these vaccines are unable to act therapeutically as L1 is 




little cross-protectivity and don’t cover the full spectrum of HR HPVs, with some of the HR non-vaccine 
types, such as HPV-35, being more prevalent in low-income countries than in high-income countries 
(Smith et al., 2007, De Sanjose et al., 2010, Malagón et al., 2012). However, there are a few strategies 
in the making to overcome these challenges.  In order to decrease the cost of the vaccine, VLPs could 
be made using different expression systems. Currently, the Gardasil® vaccines are produced in yeast 
(Saccharomyces cerevisiae) (Inglis et al., 2006) with L1 being produced in the cell and then the VLPs 
being assembled using in vitro disassembly-re-assembly methods (Shi et al., 2007). The VLPs in the 
Cervarix® (GlaxoSmithKline) vaccine are produced similarly using recombinant baculoviral vectors in 
insect cells (Trichoplusinia) (Shi et al., 2007). While these systems have successfully produced HPV 
vaccines for years, studies have shown that producing vaccines in plants could decrease the cost of 
raw product by up to 31% (Rybicki, 2009) and that HPV VLP vaccine candidates have been successfully 
produced in plants before (Maclean et al., 2007). Moreover, several different second generation 
vaccines are currently being developed to broaden the spectrum of protectivity by e.g. using L2 within 
the VLPs to increase cross-protectivity (Schellenbacher et al., 2013) and by e.g. targeting the early 
expressed genes/proteins to treat already infected individuals (Almajhdi et al., 2014, Öhlschläger et 
al., 2006). 
1.4.2. HPV pseudovirions (PsVs) 
Pseudovirions (PsVs) are L1/L2 VLPs that encapsidate up to 8Kb of DNA of the researcher’s choosing. 
They are used as infectious challenge material, for studying the viral life cycle, testing neutralising 
antibody producing vaccines and for delivering DNA into foreign cells.   
PsVs differ in their make-up to VLPs in that they contain specific DNA (of the researcher’s choosing) 
and require L2 as well as L1 in order to be functional and deliver the DNA (Wang and Roden, 2013). 
This is because L2 has  been implicated in facilitating endosome escape (Florin et al., 2006, Richards 
et al., 2006), DNA trafficking into the nucleus (Day et al., 1998, Kondo et al., 2009, Florin et al., 2006), 
aiding in capsid assembly (Chen et al., 2011, Day et al., 1998, Ishii et al., 2005, Kirnbauer et al., 1993),  
DNA packaging in certain PV strains (Holmgren et al., 2005, Zhao et al., 1998) and enhancing infectivity 
of PsVs (Buck et al., 2008, Guan et al., 2017).  Furthermore, a functional PsV encapsidates a 
pseudogenome of up to 8Kb and it does so without the use of an encapsidation signal (Stauffer et al., 
1998, Touze, 1998, Touze and Coursaget, 1998, Cerqueira et al., 2016, Cerqueira et al., 2017, Buck et 
al., 2004), meaning literally any sequence can be encapsidated.  
The first successful methods to produce DNA-encapsidating papillomavirus (PV) particles initially used 
in vitro chemical disassembly and reassembly. These studies were able to successfully produce PV 




PV particles are able to encapsidate DNA in the absence of L2 (Touze and Coursaget, 1998, Zhao et al., 
1998, Unckell et al., 1997, Müller et al., 1995, Yeager et al., 2000). However, yields of PsVs obtained 
from these methods were quite low. Alternative intracellular methods of PV production were also 
developed. Early versions of the intracellular methods included the use of viral vectors, such as Semiliki 
Forest virus (SFV) and vaccinia virus for mammalian cells and baculoviral vectors for insect cells, to 
enhance replication of the DNA.  However, PsV and virion production from these systems was not very 
efficient which led to the development of the current gold standard for producing HPV PsVs, an 
intracellular mammalian expression system designed by Buck et al. (2004). This method is a product 
of over 10 years’ worth of research (1993-2004)  (Touze and Coursaget, 1998, Zhao et al., 1998, Unckell 
et al., 1997, Müller et al., 1995, Yeager et al., 2000) and was able to increase particle production 
efficiency by 10 million-fold compared to the previous Semiliki Forest viral vector-based methods 
(Buck et al., 2004). This protocol expresses and assembles PV PsVs in Human Embryonic Kidney 
(HEK293TT )cells which contain a plasmid constitutively expressing the large T-antigen which enhances 
transgene DNA replication by binding to the SV40 origin of replication on the plasmids (Buck et al., 
2004).  Moreover, this method has shown to produce approximately 109 PV transducing units/ml and 
PsVs in these cells have further been shown to also be effective for  use in pseudovirion-based 
neutralisation assays (PBNAs) (Pastrana et al., 2004a).  However, though this method is well thought-
out and results in high titres of PsVs, it is an expensive process and requires specialised equipment 
and skills as well as carries the risk of contamination by mammalian pathogens and possibly 
oncogenes. Thus, given the importance of HPV PsVs, it may be worthwhile to try and develop 
alternative methods for producing HPV PsVs cheaply and safely. 
 
1.5.  HPV PsV applications 
HPV PsVs are important for the development of broader ranged prophylactic vaccines as they are used 
in pseudovirion-based neutralisation assays (PBNAs) to test for neutralising antibodies in response to 
new HPV vaccines (Pastrana et al., 2004b) and HPV PsVs have the potential to deliver therapeutic DNA 
(Lin et al., 2010, Chabeda et al., 2018). PsVs are also a safer alternative for use in these applications, 
compared to live or attenuated virions, as they do not contain any viral DNA. 
1.5.1. PsV-based neutralisation assays  
PBNAs have become the preferred method of testing neutralising antibody producing vaccines.  An 
HPV PBNA generally comprises of L1/L2 PsVs encapsidating a reporter gene and these PsVs are 
incubated with antisera on mammalian cells. In the event that the antiserum (taken from vaccinated 




so prevent the DNA of interest from entering the cell and being expressed and so no signal would be 
obtained (Pastrana et al., 2004b). PBNAs were first shown to be more successful than the Enzyme-
linked Immunosorbent Assay (ELISA)-based methods by Pastrana et al. in 2004. The old ELISA methods 
used labelled antibodies to outcompete the antibodies in the serum for binding to the VLP (Yeager et 
al., 2000, Dillner, 1999), and so the more signal obtained, the less antibody was present in the sera. 
These ELISAs, though, are unable to differentiate between cross-reactive and type-specific antibodies 
and are also unable to distinguish between neutralising and non-neutralising antibodies (Pastrana et 
al., 2004b). Thus, PBNAs are necessary to determine the efficiency of neutralising antibody producing 
vaccines.  
 
1.5.2. PsVs in viral life cycle studies  
The development of HPV PsVs have been seminal in advancing viral life cycle studies. An example of 
this is a study done by Day et al. in 2008 which used in vitro neutralization assays to determine the 
mechanism of HPV-16 infection. This was done using HPV 16 PsVs encapsidating fluorescent marker 
genes. Neutralization with L1 and L2 antibodies revealed that the virus undergoes conformational 
changes to allow for infectivity, with reporter gene signalling patterns being absent when the antibody 
bound an exposed epitope. Thus, it was shown that L2 is needed to be exposed and undergo furin 
cleavage before it can infect the cell (Day et al., 2008). 
1.5.3. PsV DNA delivery 
HPV infects epithelial cells, with different strains infecting either the cutaneous or mucosal epithelial 
tissue.   PsVs can also specifically target cancer cells, such as melanomas and carcinomas, that evolve 
to display the form of HSPG usually only found on the basement membrane and basal cells of the skin  
(Kines et al., 2009). These traits make PV PsVs valuable assets for the delivery of heterologous DNA 
into foreign cells, specifically for targeted gene and cancer therapies.  
 
There are currently no therapeutic HPV vaccines on the market, but considerable research has been 
done on potential candidates. The current prophylactic vaccines are not effective against established 
infections. This is due to the fact that when HPV persists, L1 and L2 are only expressed in the late 
stages of infection and so would not be available to stimulate an immune response (Schiller and Lowy, 
2012). DNA vaccines appear to be one of the best candidates for an HPV therapeutic vaccine. This is 
because they are easily produced and generate cytotoxic lymphocyte (CTL) responses whereas most 
vaccines only produce antibody responses and weak CTL responses (Pachuk et al., 2000). However, 
naked DNA vaccines have low infectivity of target cells, particularly mucosal cells, and are unable to 





HPV PsVs are potentially effective vectors for targeted delivery of therapeutic DNA as they can target 
cutaneous and mucosal epithelia as well as cancer cells specifically. Thus far, there have only been a 
few studies that have successfully shown PsV-mediated therapeutic DNA delivery in mammals. Two 
studies, one by Peng et al. (2010), and the other by Graham et al. (2010), used HPV PsVs to deliver 
antigens. These studies showed that the PsVs were able to target the correct epithelial cells and 
produced a more intense cytotoxic response to the antigen than the naked DNA (Peng et al., 2010, 
Graham et al., 2010). A study by Gordon et. al., (2012) indicated that HPV PsVs could be used to deliver 
SIV Gag genes into the genital mucosa. This PsV in combination with the SIV Gag were able stimulate 
both local and systemic effects (Gordon et al., 2012). Another study by Hung et al., (2012), utilised 
HPV-16 PsVs encapsidating the HSV-tk (herpes simplex virus thymidine kinase) gene to treat ovarian 
cancer (Hung et al., 2012). The PsVs were used to infect the ovarian tumour cells, allowing them to 
express the HSV-tk protein which activates the prodrug, ganciclovir, causing a halt in DNA replication 
and eventually apoptosis of the cells. The results of this study showed that the PsVs containing the 
HSV-tk had significantly higher cytotoxic and antitumour effects compared to the PsV control and that 
HPV PsVs preferentially infected the tumour cells as opposed to the normal, healthy cells. Finally, a 
study by Bousarghin et. al. (2009) was able to deliver DNA encoded short hairpin RNA (shRNA) into 
CaSki and TCI HPV positive cells which caused E6/E7 degradation and thereby allowed for cell death 
to occur and block tumour progression (Bousarghin et al., 2009). Thus, these studies suggest that HPV 
PsVs are an effective vehicle for targeted therapeutic DNA delivery. 
HPV PsVs, however, are currently produced in mammalian cells using the Buck et al., 2004 protocol. 
This method is expensive, requires specialised equipment and expertise and also carries the risk of 
contamination by mammalian pathogens and oncogenes. An alternative option to mammalian cell 
production is in planta HPV PsV production. While HPV PsV production in plants is still relatively new, 
there being only one published study to date (Lamprecht et al., 2016), HPV VLPs have been produced 
in plants for several years (Santi et al., 2006, Zahin et al., 2016, Maclean et al., 2007) and so there is 
still considerable potential for plant-made HPV PsVs.   
 
1.6. Plant Expression Systems 
Plants have been used as expression systems for heterologous proteins for many years (Giddings, 
2001). They are known to be a potentially safer, more easily handled and highly scalable expression 
system compared to mammalian, insect and yeast cell expression systems (Ma et al., 2003, Lico et al., 




endotoxins (Rybicki, 2010, Rybicki, 2014).  Furthermore, plants have the advantage over other 
expression systems in that they post-translationally modify proteins similar to humans (Margolin et 
al., 2018, Ma et al., 2003, Faye et al., 2005), whereas insect and yeast cells’ are limited in their 
glycosylation abilities  (Chen and Lai, 2013). Expression in plants can also be easily upscaled with little 
cost when doing Agrobacterium-mediated transient expression in Nicotiana benthamiana (Giddings, 
2001, Goodin et al., 2008). Various plants have been used so far for recombinant protein expression, 
including potato, alfalfa and Arabidopsis thaliana. However,  N. benthamiana appears to be superior 
as they produce the most biomass (Giorgi et al., 2010, Rybicki, 2009, Rybicki, 2010, Rybicki, 2014) and 
are classified as a  non-food stuff, thereby ensuring that the transgenic plants cannot contaminate 
food stock.  Moreover, producing PsVs in plants has shown to be more cost effective, as studies have 
shown that the cost of production could be significantly reduced given that no transfection reagents 
and no cell culture media are required. Several companies are starting to invest in plant-made vaccines 
and therapeutics. Medicago Inc. is the first company to successfully get a plant-made product close to 
market, after having produced a candidate H7N9 avian influenza vaccine in 1 month instead of 6. 
Medicago Inc. also have many ongoing projects and clinical trials for plant-made human therapeutics 
(Lomonossoff and D’aoust, 2016). Another notable advancement in plant-made therapeutics was the 
production of ZMapp antibodies in plants against the Ebola virus (Qiu et al., 2014). Thus, it may be 
more feasible to produce VLPs and PsVs in plants as it is potentially safer and could potentially 
decrease the cost of production and make vaccine research less expensive. 
The current HPV L1 VLP vaccines are made in yeast (Gardasil®, Merck) and insect cells (Cervarix™, 
GlaxoSmithKline), however, research has shown that HPV particles can be made in plants (Rybicki, 
2010, Rybicki, 2014, Giorgi et al., 2010, Hefferon, 2014). HPV VLPs have been made by both stable 
transformation and transient expression, with the transient production system being faster and 
resulting in higher yields and better immunogenicity (Rybicki, 2010, Rybicki, 2014, Giorgi et al., 2010, 
Hefferon, 2014). HPV 16 and 11 L1 VLPs were first made in transgenic tobacco and potato tubers.  
Although L1 was able to be expressed and VLPs were formed in these studies, yields were found to be 
below the 1% total soluble protein (TSP) threshold for commercial value and the VLPs produced were 
either very weakly immunogenic or not immunogenic at all (Biemelt et al., 2003, Warzecha et al., 2003, 
Varsani et al., 2003). Thus, transient expression was then used to try increase yields and the speed of 
production (Rybicki, 2010, Rybicki, 2014, Giorgi et al., 2010, Hefferon, 2014). Transient expression by 
a full viral vector, was the first method to be used (Varsani et al., 2006). These vectors transfer nucleic 
acid by either inoculating the plant with the viral nucleic acid, edited to contain the transgene, or by 
infecting the plant with the full viral particle to facilitate the transfer of the transgene into the plant 




in the plants from the nucleic acid, are used to transfer the recombinant nucleic acid from plant cell 
to  plant cell (Gleba et al., 2004). Moreover, the viral replication of the nucleic acid generates high 
copy numbers and thereby enhances gene expression. Successful transient expression of HPV 16 L1 
was first achieved using this method, by Varsani et al. 2006 , where recombinant TMV viral vectors 
were used to infect tobacco plants with L1 containing viral RNA. Though, this study achieved ten-fold 
higher yields of L1 protein than the transgenic models, the L1 generally only formed capsomeres and 
only stimulated a weak immune response (Varsani et al., 2006). A. tumefaciens mediated transient 
expression was attempted next.  
Expression by A. tumefaciens involves the stimulation of the vir genes, on the Agrobacterial Ti plasmid, 
to release the T-DNA from the plasmid and facilitate the translocation of the T-DNA into the plant host 
and its nucleus (Zupan et al., 2000, Tzfira et al., 2004, Komarova et al., 2010). This method of 
production has been shown to be highly scalable compared to previous methods and is faster 
(Komarova et al., 2010). Using this method, Maclean et al. demonstrated the first highly successful 
production of HPV VLPs in plants, achieving up to 14.9% TSP, which was even better when human 
codon optimised L1 was targeted to the chloroplast (17% TSP, Maclean et al., 2007). Furthermore, 
deconstructed viral vectors in combination with A. tumefaciens-mediated transfection have been used 
to try and further increase the replication and expression of transgenes in plants. These deconstructed 
viral vectors lack unnecessary and limiting genes, such as the capsid protein gene and  they include 
vectors such as the magniCON vector (Gleba et al., 2004) and the pRIC 3.0 vector (Regnard et al., 
2010). The magniCON vector consists of a deconstructed TMV genome that contains a transgene. This 
vector enhances gene expression by generating high levels of RNA replicons in plants and uses the 
TMV movement protein for cell-to-cell movement of the RNA replicons. This method has been used 
in several studies, the most recent of which reports L1 protein yields of up to 2.5% TSP (Zahin et al., 
2016). Moreover, pRIC 3.0 has also been shown to increase L1 protein yield by increasing L1 dsDNA 
replicon copy numbers by 100-fold, compared to that produced by the non-replicating pTRAc vector 
(Regnard et al., 2010). Additionally, the pRIC vector has been successfully used as a vector for plant 
produced HPV PsV pseudogenomes.  
Production of HPV PsVs  in plants have been reported once previously (Lamprecht et al., 2016). This 
study indicated that HPV L1 and L2 and a pseudogenome based on the replicating vector pRIC could 
be expressed in plants and that the PsV particles could assemble correctly in the plant. It also 
demonstrated that plant-made HPV PsVs functioned similarly in PBNAs to mammalian cell-produced 
HPV PsVs.  However, one current issue with in planta production of HPV PsVs is the low yield of PsV 
vs VLPs obtained. One way in which yields of stable HPV PsVs were shown to improve, in other 




an HPV particle. HPV is known to encapsidate linear or circular DNAs by size, with the theory being 
that PV PsVs are in constant state of disassembly and reassembly but once they encounter DNA of an 
appropriate size below 8Kb, they form a stable particle that is resistant to disassembly (Stauffer et al., 
1998, Zhao et al., 1998, Buck et al., 2004, Touze and Coursaget, 1998, Cerqueira et al., 2016). The 
study by Lamprecht et al. used two different sized pseudogenomes in their experiments, the smaller 
of the two resulting in better transduction. This was the first indication that plant-made HPV PsVs may 
encapsidate DNA similarly to mammalian HPV PsVs and that, by altering the size of the 
pseudogenome, yields of PsVs vs VLPs could potentially be improved.  Thus, by improving yields of 
stable HPV PsVs produced from plants, the cost of production of PsVs and all its downstream 
applications could decrease, and the safety could increase.  
 
1.7. Project Aims and Objectives 
HPV is known to be the cause of anogenital and oropharyngeal cancers as well as genital and common 
warts. The burden of HPV however is highest in low-income countries, for whom the vaccine costs are 
still high, and so alternative methods of vaccine production and testing are needed. HPV PsVs are 
important for studying, protecting against and treating HPV infections. Plants represent a potentially 
safer, cheaper and more easily scalable means of production of PsVs. However, plant PsVs studies are 
relatively new and still require some optimisation, particularly where yield is concerned. Nevertheless, 
research has shown that using pseudogenome DNAs between 5-7Kb increases yields of stable 
papillomavirus PsVs in mammalian cells. Therefore, this study aimed to optimise the production HPV 
PsVs in Nicotiana benthamiana by determining the optimal size of DNA required for in planta HPV PsV 
encapsidation.  
The objectives set out to achieve this goal were as follows: 
1. To clone the different sized pseudogenomes: 
The first objective of this project was to clone pseudogenomes of 4.8Kb, 5.8Kb, 6.8Kb and 
7.8Kb in size, using the EGFP and luciferase reporter genes in a geminivirus-derived replicating 
vector to allow for enhanced DNA replication.  
 
2. To express and purify the PsVs with the different sized pseudogenomes in tobacco plants: 
The second objective was to express and purify the PsVs by infiltrating the different sized 
pseudogenomes into Nicotiana benthamiana along with plant expression vectors encoding 





3. To characterise the PsVs containing the different sized pseudogenomes: 
The third objective was to characterise the PsVs produced with the different sized 






Chapter 2: Cloning of different sized pseudogenomes 
 
2.1 Introduction 
HPV is a dsDNA virus whose virions are composed of the L1 major capsid protein and the L2 minor 
capsid protein encapsidating a circular genome of 8Kb, complexed with host histones so as to form 
compact “minichromosomes”. HPV pseudovirions (PsVs) are L1/L2 VLPs that have encapsidated  up to 
8kb of dsDNA, without the obvious use of DNA encapsidation signals (Stauffer et al., 1998).  
2.1.1. Encapsidation by size discrimination  
Lamprecht et. al (2016) showed that HPV 16 PsVs can be produced in plants, and that these PsVs can 
be used in in vitro neutralization assays with mammalian cells (Lamprecht et al., 2016). This is 
advantageous over mammalian cell produced PsVs as it reduces the possibility of contamination with 
mammalian pathogens which are not able to infect plant cells, and mammalian oncogenes which are 
not present in plant genomes. Plant production could also significantly reduce the cost of PsV 
production (Rybicki, 2009).  However, a current limitation with PsV production in plants is low yields. 
While it is known that any type of DNA less than 8Kb can be encapsidated, studies have found that 
encapsidation efficiencies do vary according to the size of the pseudogenome (Stauffer et al., 1998, 
Touze and Coursaget, 1998, Zhao et al., 1998, Roden et al., 1996, Cerqueira et al., 2016, Buck et al., 
2004). Buck et al. showed that using pseudogenome DNA between 5-7Kb could increase the yield of 
bovine papillomavirus (BPV1) PsVs produced in mammalian cells: higher yields of PsVs were obtained 
when DNA of 5.9kb was encapsidated compared to when 7.9Kb was encapsidated. With this in mind, 
the authors hypothesized that the L1/L2 VLPs may be in a constant state of assembly and disassembly 
until they are able to encapsidate DNA smaller than 8kb, and only then are they able to produce a 
stable VLP structure (Buck et al., 2004). Cerqueira et al, (2016) provided more evidence for this theory 
by showing that the HPV PsVs encapsidating DNA smaller than 8Kb were stable, and did not 
reassemble even in the presence of DNA of the correct size (Cerqueira et al., 2016). Furthermore, 
Lamprecht et al. (2016) found that DNA encapsidation size might be important for plant-made HPV 
PsV formation as a 4.8Kb pseudogenome was found to produce more signal in infectivity assays than 
the 6.6Kb pseudogenome, indicating that the 4.8Kb pseudogenome may have been more efficiently 
packaged than the 6.6Kb pseudogenome. Thus, by experimenting with different sized 
pseudogenomes, the optimal encapsidation size for plant-made HPV PsVs could be elucidated and 




2.1.2. Use of reporter genes in pseudogenomes  
PsVs can be used in PsV-based neutralisation assays (PBNAs) to test a vaccine candidate’s ability to 
elicit neutralising antibodies. An HPV PBNA utilises PsVs encapsidating a reporter gene; these PsVs are 
incubated with antisera before being put on mammalian cells. If the antiserum is neutralising, the 
antibodies bind the PsVs, which prevents them from infecting the cell, which in turn prevents the 
reporter plasmid from entering the cell, being expressed, and producing a signal. These PBNAs can 
become expensive depending on the reporter gene used. For example, the SEAP detection kit is 490 
USD/1000 rxns; this could make the testing of neutralising antibody vaccines very expensive.  The cost 
of PBNAs could be kept to a minimum by using fluorescent protein reporter genes, which don’t require 
substrates, or luciferase reporter genes which have a detection kit that is approximately one third of 
the price of the SEAP kit. Thus, by using cost effective reporter genes, the cost of PBNAs could be kept 
at a minimum and thereby the cost of testing new, neutralising antibody producing vaccines could be 
kept down. 
2.1.3. Plant viral vectors for encapsidation of pseudogenomes 
A strategy to optimize encapsidation efficiency in plants is to create an overabundance of the plasmi-
like pseudogenome in the plant cell. This is potentially achieved by using autonomously replicating 
plasmid-like DNA plant virus-derived expression vectors to replicate the pseudogenome DNA in the 
plant. Geminiviruses are one such family of viruses. They are small, ssDNA viruses that use rolling circle 
replication to replicate continuously and autonomously in plants. Geminiviruses, and particularly bean 
yellow dwarf virus (BeYDV), have been successfully used in several studies to  enhance expression of 
transgenes in plants  (Mor et al., 2003, Hefferon and Fan, 2004, Zhang and Mason, 2006, Regnard et 
al., 2010, Huang et al., 2009). BeYDV has an ambisense genome that replicates autonomously in 
plants. The mechanisms by which it does this were exploited by Regnard et. al., in 2010 to make the 
pRIC3.0 vector (Figure1). The pRIC 3.0 vector design was based on a mild strain of BeYDV (Halley-Stott 
et al., 2007) and was designed for Agrobacterium tumefaciens mediated transient expression in plants. 
The vector contains the left and right border sequences which are cleaved by the A. tumefaciens vir 
genes in order to release the T-DNA into the plant cell nucleus (Komarova et al., 2010, Zupan et al., 
2000). This T-DNA is the component of the pRIC 3.0 vector that contains the self-excising BeYDV 5’LIR-
SIR-rep-3’LIR element, and it is in between the 5’LIR and the SIR that the desired pseudogenome 





Figure 1:  Schematic representation of the pRIC 3.0 vector and the resulting replicons containing the sequences of interest. 
a) The pRIC 3.0 vector. Indigo, origin of replication for E. coli; lilac, RK2 ori, origin of replication for Agrobacterium 
tumefaciens; peach, bla gene for ampicillin⁄carbenicillin resistance; orange arrows, left (LB) and right borders (RB) for T-DNA 
integration; light green, P35SS CaMV 35S promoter with duplicated transcriptional enhancer; dark green, CHS, chalcone 
synthase 5`-untranslated region; light blue, pA35S, CaMV 35S polyadenylation signal; orange, LIR, BeYDV long intergenic 
region; red, SIR, BeYDV short intergenic region; dark blue, rep, BeYDV rep gene. The black bar within the vector indicates the 
components of the vector that become the replicon. b) the pRIC replicon, replicated in the plant from the pRIC 3.0 vector.  
The pRIC replicon contains the rep gene, SIR, one LIR, CHS, P35SS CaMV 35S promoter and the pA35S polyadenylation signal.  
The gene/sequence of interest is cloned into the multiple cloning site in between the CaMV 35S promoter and the CaMV 35S 
polyadenylation signal of the pRIC 3.0 vector and is therefore present in the pRIC 3.0 replicon. c) Diagram of all the 
pseudogenome replicons formed from the pRIC 3.0 constructs cloned in this study. The schematic of pRIC 3.0 and it’s replicon 
was created using Benchling (Benchling [Biology Software]. 2019. Retrieved from https://benchling.com) and information 
obtained from Regnard et. al., (2010). 
  
BeYDV elements were added to the pRIC vector. This allows for the production of small replicons in 




and the short intergenic region (SIR) but has an extra copy of the long intergenic region (LIR, Figure 1). 
The LIRs are stem-loop structures that contain bidirectional promoters and origins of replications. 
Their duplication is essential for the formation of the small replicons in the plant nucleus as the Rep 
protein initiates replication by binding to them and nicking them. The sense and complementary 
strands of the vector are separated by the SIR with the region between the SIR and the 3’LIR being the 
complimentary strand of the vector. The SIR contains a primer binding site that allows for the initiation 
of replication of the complimentary strand and the Rep/RepA proteins are transcribed from the rep 
gene on this strand, using the 3’ LIR promoter and plant host machinery. The rep transcript is then 
alternatively spliced to create the Rep and RepA proteins (Liu et al., 1998, Gutierrez, 1999) . The RepA 
protein is responsible for keeping the plant cell cycle in S-phase (Hefferon and Dugdale, 2003, Liu et 
al., 1999, Liu et al., 1998), while the Rep protein is responsible for initiating replication of the sense 
strand. The Rep protein initiates replication by nicking the LIR stem loops, which stimulates DNA repair 
of the sense strand, and a new strand replaces the old one. Rep remains bound to the 5’ end of the 
original, displaced sense strand and allows for the recircularization of the strand and thus the 
formation of a small replicon (Laufs, 1995b, Laufs, 1995a, Gutierrez, 1999). From this replicon, a dsDNA 
intermediate is made and more Rep/RepA is expressed. Consequently, an increased production of Rep 
results in an increase in the number of replicons produced. This triggers more Rep to be expressed 
and thus creates a continuous cycle of autonomous replication. In the absence of coat protein, the 
replicons are rapidly and efficiently converted to dsDNA. 
This pRIC vector was used by Lamprecht et al. (2016) to construct the mSEAP (mammalian SEAP 
expression cassette, 4.8Kb) pseudogenome, which was used to successfully produce the first 
published HPV PsVs produced in planta. Replicon copy number has been shown to be amplified up to 
1000-fold in plants (Regnard et al., 2010), and the dsDNA intermediate form of these replicons is 
encapsidated to form the PsVs. Thus, pRIC allows for replication of recombinant pseudogenome DNA 
and therefore increases the likelihood of encapsidation of the pseudogenome replicons. 
2.1.4. Pseudogenome replication and expression 
To make functional HPV PsVs, L1/L2 particles must encapsidate DNA in plants and deliver this DNA 
into mammalian cells where it can be expressed. Plant-made HPV pseudogenomes replicate in the 
form of the parent plasmid in E. coli and Agrobacterium tumefaciens, and in the form of the derived 
replicon in plants. However, expression cassettes need to be designed so that the gene(s) of interest 
is only expressed in mammalian cells to avoid oversaturating the plant cell with expressed protein. In 
this study, the cytomegalovirus (CMV) enhancer and promoter was used for the luciferase gene 
expression cassette of the 7.8Kb pseudogenome. The CMV promoter is known to be a very strong 




especially when combined with the strong transcription termination signal used in this study, 
WPRE/BGH. The pSHELL vectors, commonly used to produce high yields of mammalian HPV PsVs, 
make use of the  bovine growth hormone (BGH) poly-A-tail and the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) to create a strong transcription termination signal, 
when using the CMV promoter (Buck et al., 2006b, Real et al., 2011). The EGFP reporter gene, present 
in all the pseudogenomes used in this study, is under the control of the SV40 promoter/enhancer and 
the SV40 polyadenylation signal. These transcription regulatory elements have been known produce 
high levels of recombinant gene expression in mammalian cells, specifically in HEK293TT cells. This is 
due to the SV40 poly-A-tail, which allows for efficient post-transcriptional processing (Van Den Hoff et 
al., 1993), and the SV40 origin of replication, which overlaps the SV40 promoter and allows for 
increased DNA replication in HEK293TT cells. HEK293TT cells have been modified so that they produce 
the SV40 small t-antigen and the large T-antigen. The large T-antigen enhances replication by binding 
to the SV40 origin of replication and increasing copy number and thereby gene expression in 
HEK293TT cells (Buck et al., 2005a, Buck et al., 2004). These cells are essential for the production of 
HPV PsVs in mammalian cells, for testing PsV infectivity and for PBNAs (Buck et al., 2006a). Thus, all 
pseudogenome constructs used in this study were created with an SV40 origin of replication to ensure 
high copy number generation in HEK293TT cells, and strong mammalian expression cassettes to 
ensure high levels of gene expression. 
This chapter describes the cloning of HPV pseudogenomes sized 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb using 
the pRIC 3.0 vector to generate high copy numbers for encapsidation, and strong mammalian 
expression cassettes are used to produce high levels of EGFP or luciferase reporter gene expression. 
These constructs provide the pseudogenomes that will be used to determine optimal pseudogenome 
encapsidation size for plant-made HPV PsVs.  
 
2.2. Methods 
2.2.2. Plasmid isolation and restriction enzyme digestion 
Plasmids were isolated from E. coli and Agrobacterium tumefaciens using the QIAprep Spin Miniprep 
kit (QIAGEN, Germantown, USA) as per the manufacturer’s instructions. All restriction enzymes used 
were procured from ThermoFischer Scientific, except for AflIII which was obtained from New England 
Biolabs (NEB, Ipswich, USA).  All restriction enzyme digestions were performed as per the 
manufacturer’s instructions. Some sequential digestions were performed and cleaned up using the 
QIAquick Nucleotide Removal Kit between digests (QIAGEN, Germantown, USA). DNA bands from PCR 
and restriction enzyme digests, which were used for cloning, were gel extracted using the QIAquick 




2.2.3. Ligation and transformation into E. coli 
Blunt end cloning into the pJET intermediate vector was performed, using the CloneJET PCR Cloning 
Kit (ThermoFischer Scientific, Waltham, USA), when restriction sites were added to insert DNA by HI-
FI PCR. The inserts were digested, and gel extracted from pJET using the appropriate enzymes and 
ligated into the final vector. Vector DNA was always dephosphorylated with rAPid Alkaline 
Phosphatase (Roche, Basel, Switzerland) when cloning with compatible ends, as per the 
manufacturer’s instructions. T4 DNA ligase (ThermoFischer Scientific, Waltham, USA) was used, as per 
the manufacturer’s instructions, in 16hr overnight ligations, to ligate all the inserts into their vectors.  
Clones were transformed by adding 4µl of ligation mixture to 15µl NEB® 10-beta chemically 
Competent E. coli (NEB, Ipswich, USA) and then performing the transformation as per the 
manufacturer’s instructions. All pRIC 3.0 constructs, pJET, pCLucf and mSEAP contained the bla 
ampicillin/carbenicillin resistance gene and thus the DH10β cells were grown  overnight at 37˚C in Luria 
Broth (LB: 10g/L Bacto-tryptone, 5g/L yeast extract, 10g/L NaCl, up to 1L water) or Luria Agar (LB, 
15g/L agar) supplemented with 100µg/ml of Ampicillin. 
 
2.2.4. Polymerase chain reaction (PCR) 
The EGFP, CMV-Luciferase and all the stuffer fragments (random DNA fragments used to increase 
replicon size) were all cloned into the vectors using PCR.  Primers were designed to add restriction 
enzyme recognition sites onto the 5’ and 3’ ends of the desired sequences (Table. 1). The pCLucf 
plasmid, a gift from Dr. John Schiller (Addgene, Watertown, Massachusetts, USA, plasmid # 37328; 
http://n2t.net/addgene:37328 ; RRID:Addgene_37328) was used as a template for the EGFP and CMV-
Luciferase sequences. The 1Kb and 1.5Kb stuffer fragments were amplified from the luciferase gene 
in the pCLucf plasmid and the 0.5Kb stuffer was amplified from the E1a sequence of the mSEAP 
plasmid (Lamprecht et al., 2016).  The Q5® High-Fidelity DNA Polymerase (NEB, Ipswich, USA) was 
used to amplify the desired sequences as per the manufacturer’s instructions. Annealing temperatures 
used were 65°C for the EGFP gene amplification, 60°C for the stuffer fragment PCRs and 70°C  for the 
luciferase gene PCR. Amplicons were purified by agarose gel electrophoresis and gel extraction and 
then ligated into pJET (CloneJET PCR Cloning Kit, Thermo Fisher Scientific, Waltham, USA). Final inserts 
were obtained by restriction enzyme digestion of pJET and purification of the DNA by agarose gel 
electrophoresis and gel extraction. 
 
Colony PCR (Mirhendi et al., 2007) was used to screen for recombinant colonies, using insert specific 
primers and vector specific primers where possible. Colonies were resuspended in 10μl of water and 




Master mix RED (AMPLIQON III, Odense, Denmark), following the manufacturer’s recommendations. 





Table 1: Primers used for cloning, screening and sequencing of putatively positive clones. 
PRIMER SEQUENCE (5’- 3’) AMPLIFIED FROM RE SITE ADDED TM (˚C) PURPOSE 
STUFFER 1000BP FOR ATTGCTAGCTTCAACGAGTACGACTTCGTG  pCLucf 5’ NheI 62 Cloning, screening  
STUFFER 1500BP FOR TATGCTAGCCATTCTACCCACTCGAAGACG  pCLucf 5’ NheI 63 Cloning, screening  
STUFFER 1000_1500BP 
REV 
ATAAAGCTTAGCTTCTTGGCGGTTGTAACCTG  pCLucf 3’ HindIII 62 Cloning, screening  
STUFFER 500BP FOR TTAAAGCTTAATACCAGTGTGCAGATCTTGGC  mSEAp 5’ HindIII 61 Cloning, screening  
STUFFER 500BP REV ATTGAGCTCGTAAACTGGGAAAGTGATGTCGTG  mSEAp 3’ SacI 63 Cloning, screening  
EGFP 5’ SPEI FOR TTAACTAGTATGGTGAGCAAGGGCGAGGAGCTG  pCLucf 5’ SpeI 69 Cloning, screening, sequencing  
EGFP 3’ XHOI REV TATTCTCGAGTTACTTGTACAGCTCGTCCATGCC  pCLucf 3’ XhoI 68 Cloning, screening, sequencing 
CMV-LUC 5’ PACI FOR ATATTAATTAACGCCACCTCTGACTTGAGCGTCGA  pCLucf 5’ PacI  69 Cloning, sequencing 
CMV-LUC REV CCAAACTCATCAATGTATCTTATCATGTCTGCTCG  pCLucf -  65 Cloning, sequencing 
CMVLUC INNER FOR ATAGCTTGCAGTTCTTCATGCC pCLucf -  60 Sequencing  




2.2.5. Generation of multiple sized pseudogenome constructs 
Different sized pseudogenome constructs were cloned such that their replicons would be 4.8Kb, 
5.8Kb, 6.8Kb and 7.8Kb in size.  
2.2.5.1.  Synthesis of mammalian expression cassette 
A mammalian expression cassette was designed for the cloning of EGFP and CMV-Luciferase into the 
different sized pseudogenomes and this expression cassette was synthesised by GenScript USA Inc. 
(Piscataway, USA). The expression cassette contains an SV40 origin of replication and an SV40 
enhancer-promoter and poly-A-tail between which the EGFP gene can be cloned. A WPRE 
transcription terminator and a BGH poly-A tail were also added so that the CMV promoter and 
luciferase gene could be cloned in downstream of the EGFP cassette. This fragment was received in 
the pUC57 vector and is therefore known as pUC57-synth (Figure 2).  
 
 
Figure 2: Schematic of pUC57-synthesised mammalian cassette. Fragment contains sites for cloning of the EGFP 
gene between the SV40 promoter and poly-A tail via the 5’ SpeI and 3’ XhoI restriction sites.  Fragment also 
contains the PacI and NotI restriction sites upstream of the WPRE/BGH Poly-A-tail for the introduction of a CMV 
promoter-Luciferase cassette, downstream of the EGFP cassette. The synthesised mammalian cassette was 
received in pUC57, pUC57-synth. 
2.2.5.2. EGFP mammalian expression cassette 
The EGFP gene was modified by PCR to add 5’SpeI and 3’ XhoI restriction enzyme sites. This EGFP gene 
was then blunt end cloned into pJET and extracted and ligated into the pUC57-synth vector using the 






Figure 3: Schematic representation of the cloning of pUC57-Synth-EGFP, the EGFP mammalian expression 
cassette. The EGFP gene was cloned in between the SV40 promoter and poly-A tail using the 5’ SpeI and 3’ XhoI 
restriction sites.  
 
2.2.6. Generation of different sized pRIC 3.0 backbones 
Different sized stuffer fragments were cloned into the pRIC 3.0 vector to enable the production of 
various sized replicons. The pRIC 3.0 vector, without any modifications, produces a replicon of 3.3Kb. 
The 1Kb, 1.5Kb and 0.5Kb stuffers were created by amplifying up different sections of the luciferase 
gene in the pCLucf plasmid (1Kb and 1.5Kb stuffers) or sections of the E1a promoter of the mSEAP 
plasmid (0.5Kb stuffer). Restriction enzyme sites were also added to these stuffers by PCR. The 1Kb 
stuffer was cloned into the pRIC 3.0 vector using the 5’ NheI and 3’ HindIII sites to make a construct 
that would produce a 4.3Kb replicon. The 1.5Kb and 0.5Kb stuffers were cloned into the pRIC 3.0 vector 
sequentially, using the 5’NheI/3’HindIII sites and the 5’HindIII/3’SacI restriction enzyme sites, 
respectively, making a stuffer fragment of 2Kb. This new 2Kb stuffer construct therefore produces a 



















Figure 4: Schematic representation of the cloning of the different sized pRIC3.0 vectors. The 1Kb stuffer 
fragment was cloned into pRIC3.0 using the 5’ NheI and 3’ HindIII sites. The 1.5Kb and 0.5Kb were cloned into 
pRIC3.0 sequentially using the 5’NheI/3’HindIII sites and the 5’HindIII/3’SacI restriction enzyme sites, 
respectively. 
 
2.2.7. Cloning of different sized EGFP pseudogenomes  
The 4.8Kb, 5.8Kb and 6.8Kb pseudogenomes were created by digesting the EGFP mammalian 
expression cassette from the pUC57-Synth-EGFP vector and ligating it into the different sized pRIC3.0 
backbones, using the 5’ AflIII and 3’ NheI restriction enzymes. The backbones used for these constructs 






Figure 5: Schematic representation of the cloning of the different EGFP pseudogenomes. The EGFP mammalian 
expression cassette was digested out of pUC57-Synth-EGFP and ligated into the different sized pRIC 3.0 
backbones, using the 5’AflIII and 3’NheI restriction enzymes, to make the 4.8Kb, 5.8Kb and 6.8Kb pseudogenome 
constructs. Orange labels represent the final pseudogenome construct sizes. 
The EGFP cassette was cloned into the pRIC 3.0 empty backbone which results in a 4.8Kb replicon. The 
cloning of the EGFP cassette into the pRIC3.0 backbones containing the 1Kb and 2Kb (1.5Kb+0.5Kb) 
stuffers, result in pseudogenome replicons of 5.8Kb and 6.8Kb (Figure 5). 
 
The 4.8Kb pseudogenome construct was used to create the 7.8Kb pseudogenome. The CMV promoter 
and luciferase were amplified as one unit out from the pCLucf plasmid. The CMV-Luciferase fragment 
was cloned into pJET and then digested, extracted and ligated into the 4.8Kb pseudogenome 
construct, upstream of the WPRE/BGHA poly-A-tail, using the 5’PacI and 3’ NotI restriction enzymes. 






Figure 6: Diagram of the cloning strategy for the 7.8Kb pseudogenome construct. The CMV_promoter-
Luciferase was cloned into the 4.8Kb pseudogenome construct using 5’ PacI/3’NotI. Orange labels represent the 
final pseudogenome construct. 
 
2.2.8. Agrobacterium tumefaciens GV3101::pMP90RK  
Electrocompetent Agrobacterium tumefaciens GV3101::pMP90RK was used for infiltration of the 
plants, for all the constructs in this study. The Agrobacterium was made electro-competent using the 
methods described (Shen and Forde, 1989).  Briefly, 100μl of competent cells and 300ng of DNA were 
added to 0.1cm electroporation cuvette (BioRad, Hercules, USA) and electroporated at 1.8kV, 25μF, 
200Ω using a GenePulser (BioRad, Hercules, USA). After the addition of 0.9ml of LB media, cells were 
incubated at 27 ̊ C for 2 hours to allow for recovery and growth. The pMP90RK, helper plasmid, carries 
the antibiotic Kanamycin resistance gene, which allows for positive selection of the recombinant cells. 
The rifampicin resistance genes are carried within the Agrobacterium genome and the pRIC 3.0 vectors 
contain the Carbenicillin resistance gene. Therefore, the culture was plated and grown up on LB agar 
containing 50μg/mL, Kanamycin, 30μg/mL Rifampicin and 50μg/mL of Carbenicillin. 
 
Agrobacterium colonies were screened with PCR, back-transformed into E. coli and confirmed with 
restriction enzyme digestion.  
2.2.9. Sequencing  
The EGFP and CMV promoter-luciferase clones that were positive for both the PCR and the restriction 
enzyme digestions, were sequenced, in pJET, to ensure that no errors had occurred during the PCR.  




and vector primers (table 1). Sequences were analysed and aligned to reference sequences using CLC 
Main Workbench 6 (QIAGEN, Germantown USA). 
 
2.2.10. HEK293TT cell maintenance 
HEK293TT stock cells were grown in Dulbecco's Modified Eagle's medium  (DMEM) with 10% bovine 
foetal calf serum (v/v), 1% non-essential amino acids (v/v), 1% penicillin-streptomycin (v/v) and 
250μg/mL hygromycin, in Corning® T75 cell culture flasks (Merck, Kenilworth, USA).  Cells were grown 
in an incubator at 37˚C with 5% C02 and 95% humidity. Cells were passaged at approximately 80% 
density.  
 
2.2.11. Confirmation of reporter gene expression in HEK293TT cells 
EGFP reporter gene expression was tested using fluorescent microscopy and luciferase gene 
expression was tested using a luciferase assay. 
 
2.2.12. Fluorescent microscopy for confirmation of EGFP expression 
Square, 0.1mm thick, 22x22mm coverslips (Marienfeld Superior, Lauda-Königshofen, Germany) were 
prepared by acid washing for 4hrs at 60˚C in 1M HCl. The slides were then washed with dH2O and 96% 
ethanol and autoclaved. Next, the slides were the coated, in a 6 well Corning® Costar® TC-Treated 
plate, with 2ml of 0.1mg/ml poly-D-Lysine (10% (v/v) 1mg/ml Poly-D-Lysine solution (Merck, 
Kenilworth, USA) in 1x Gibco™ DPBS) for 2 hours at 37˚C and then dried for 1hr -1.5hrs at 37˚C. 
Following this, HEK293TT cells were seeded onto the coverslips at 150 000 cells/well. Cells were 
transfected approximately 24hrs after seeding, using Lipofectamine® 2000 Reagent (Invitrogen ™ , 
Carlsbad, USA). The transfection procedure was carried out as per the manufacturer’s instructions, 
using 2μg of DNA and 12.5μl Lipofectamine per well of a 6 well plate. After 24 hours, the cells were 
washed thrice with 1x Gibco™ DPBS and then fixed with 4% formaldehyde for 20 mins. Cells were 
washed thrice again, with 1x Gibco™ DPBS, and stained with 2mg/ml Hoechst (Merck , Kenilworth, 
USA) for 10 mins before washing and mounting onto glass slides (Marienfeld Superior, Lauda-
Königshofen, Germany) using Mowiol mounting media with propyl gallate (anti-fade) (Confocal and 
Light Microscope Imaging Facility, University of Cape Town, South Africa).  The slides were air dried at 
37˚C for 10mins. Finally, the slides were viewed under an inverted fluorescent microscope (Zeiss 
Axiovert 200M) using the 40X objective lense and the DAPI filter to view the Hoechst stained nuclei 
and the ALEXA 488 filter to view EGFP fluorescence. Images were captured and analysed with a 






2.2.12.1. Confirmation of luciferase expression  
A luciferase assay was used to test the 7.8Kb pseudogenome construct for luciferase expression. The 
luciferase assay was carried out using the Luciferase Assay System kit (Promega, Madison, USA) as per 
manufacturer’s instruction. Luminescence was read in a Corning® 96 Well White Polystyrene 
Microplate (Merck, Kenilworth, USA) using the GloMax Multi Plus luminometer (Promega, Madison, 
USA). 
 
Luminescence results were normalised to the amount of total soluble protein in the sample. Total 
soluble protein was calculated using a Bradford Protein Assay (Bio-Rad, Hercules, USA) as per the 
manufacturer’s instructions. Absorbance was read at 750nm in a Multiwell immuno polysorb plate 
(ThermoFischer Scientific, Waltham, USA). 
 
2.3. Results 
Four different sized constructs were designed so that the pseudogenome replicons being 
encapsidated would be 4.8Kb, 5.8Kb, 6.8Kb or 7.8Kb in size (Figure 7). These constructs contain the 
EGFP and luciferase reporter genes instead of SEAP and can replicate in E. coli, A. tumefaciens, plants 
and mammalian cells. However, reporter gene expression can only occur in mammalian cells.  
Figure 7: Schematic representation of the different sized pseudogenomes. EGFP, Luciferase and stuffer (Stuf.) 
fragments cloned into pRIC 3.0, so that a 4.8Kb replicon, 5.8Kb replicon, 6.8Kb replicon and a 7.8Kb replicon 
would be made in plants. 
 
2.3.2. Cloning of pseudogenomes  
A mammalian expression cassette was synthesised for the production of the different sized 
pseudogenomes (Figure 2).  EGFP was then cloned into this cassette to create an EGFP mammalian 




different sized stuffers into pRIC 3.0 (Figure 4) and from this the 4.8Kb, 5.8Kb and 6.8Kb 
pseudogenome constructs were made by cloning the EGFP mammalian cassette into these various 
sized pRIC3.0 vectors (Figure 5). The final, 7.8Kb construct was made by cloning CMV promoter-
Luciferase DNA fragment into the 4.8Kb construct (Figure 6). 
The cloning of the constructs was confirmed in E. coli with PCR and then by restriction enzyme digest 
(Figure 8). A double digest with SpeI/XhoI was used to confirm the cloning of the 4.8Kb (17 ran off, 
726, 1149 and 6323bp) and the 5.8Kb (726bp, 2170bp, 6323bp) pseudogenome constructs. The 6.8Kb 
pseudogenome construct sequence was confirmed by digesting with HindIII/XhoI (733, 2647, 6799bp), 
and the 7.8Kb pseudogenome sequence was confirmed by digesting with AgeI/NdeI (1885, 1727, 
7523bp). All the expected band sizes were obtained and the cloning of all four constructs were 
confirmed (Figure 8).  
The DNA was then electroporated into Agrobacterium tumefaciens GV3101::pMP90RK for infiltration 
into plants. The Agrobacterium colonies were screened for the constructs by PCR and then confirmed 






Figure 8: Confirmation of the pseudogenome construct sequences. Diagnostic digests were done on the 
pseudogenome DNA from PCR positive E. coli colonies. DNA in the digestions were separated by 1% agarose gel 
electrophoresis, using 0.5ug/ml EtBr to visualise the DNA bands. Uncut, undigested template DNA; MW, 
molecular weight marker, O’GeneRuler. a) Two colonies of pRIC3.0-E-4.8Kb DNA digested with SpeI and XhoI; b) 
pRIC3.0-E-5.8Kb DNA digested with SpeI and XhoI. c) pRIC3.0-E-6.8Kb digested with HindIII and XhoI. d) pRIC3.0-
EL-7.8Kb DNA digested with AgeI/NdeI.  
 
2.3.3. Confirmation of pseudogenome reporter gene expression 
DNA isolated from the positive colonies were also used to test the functionality of the pseudogenome 
expression cassettes. To confirm EGFP expression, all construct DNA was transfected onto HEK293TT 
cells and after 48hours, the cells were viewed under the fluorescent microscope to check for EGFP 
fluorescence (Figure 9).  Cells fluorescing green were observed in all the pseudogenome construct 




                                         
Figure 9: Pseudogenome constructs expressing EGFP. Cells were grown on glass slides and transfected with the 
pseudogenome construct DNA using Lipofectamine® 2000. After 48 hours, the cells were fixed with 4% 
formaldehyde and the cell nuclei were stained with Hoechst (Excitation⁄Emission (nm): 352⁄455). Coverslips 
were mounted onto glass slides using Mowiol. The DAPI (Excitation/Emission (nm): 325-375/440-480) filters 
were used to visualise the nuclei (left-hand panel) and the ALEXA 488 filters (Excitation/Emission (nm): 460-
490/510-560) were used to visualise EGFP fluorescence (middle panel). The images of the DAPI and ALEXA 488 




The 7.8Kb pseudogenome construct was also tested for luciferase expression in HEK293TT cells. 
HEK293TT cells were transfected with 7.8Kb pseudogenome construct DNA. These cells were lysed 
after 48 hours and a luciferase assay was performed on the cell lysate (Figure 10). Luciferase 
expression levels from the 7.8Kb pseudogenome construct (1.08x1010 RLU/mg tsp) were found to be 
comparable to that of the positive control (2.78x109 RLU/mg tsp) and a thousand-fold higher than that 
of the cells only control (2.78x107 RLU/mg tsp). This indicates that luciferase is expressed from the 
7.8Kb pseudogenome construct in HEK293TT cells.  
 
Figure 10: Luciferase gene expression from the 7.8Kb pseudogenome construct. HEK293TT cells were 
transfected with 7.8Kb pseudogenome DNA using Lipofectamine® 2000 and lysed after 48hours. Luciferase assay 
was carried out on the cell lysate and luminescence was read using a GloMax Multi Plus luminometer. 
Luminescence readings were corrected for background and normalised to total soluble protein (tsp). Error bars 
represent standard error between technical repeats.  
 
2.4. Discussion 
Four pseudogenome constructs with sizes of 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb were successfully cloned 
(Figure 8). These sizes were chosen for testing DNA encapsidation in plants by HPV L1 and L2 proteins, 
as literature shows that pseudogenomes 5-7Kb in size are best suited for papillomavirus PsV 
production (Buck et al., 2004, Cerqueira et al., 2016, Touze and Coursaget, 1998). Furthermore, it was 
shown in a study by Lamprecht et al. (2016) that PsVs containing the 4.8Kb pseudogenome produced 
significantly more signal in infectivity assays than the PsVs containing the 6.6Kb pseudogenome, which 
indicates that more 4.8Kb DNA was being encapsidated than 6.6Kb DNA. This is evidence that DNA 
size may play an important role in governing plant-made HPV PsV DNA encapsidation. Therefore, by 
using pseudogenomes differing by 1Kb to each other, a narrow size range for optimal DNA 




These pseudogenome constructs were made by cloning into the pRIC 3.0 vector (Figure 5, 6). The pRIC 
3.0 vector has previously been successfully used in a study by Lamprecht et al. (2016) as a 
pseudogenome vector for plant-made HPV PsVs. These PsVs were found to be able to encapsidate 
DNA and to be efficient in PBNAs. Moreover, the pRIC 3.0 vector is important for in planta PsV 
production, in that it allows for the continuous and autonomous generation of small replicons in 
plants. The rolling circle mechanism of replication that pRIC 3.0 undergoes in plant cells, has been 
shown to be able to increase the copy number of pRIC 3.0 vectors, carrying the HIV p24 antigen or the 
EGFP gene, from 106 to 1010 copies after only three days post infiltration (Regnard et al., 2010). This is 
promising because increased pseudogenome copy numbers, increases the chance of pseudogenome 
encapsidation and therefore PsV formation. Thus, lack of pseudogenome DNA availability will not 
affect encapsidation, making pseudogenome size the biggest factor affecting encapsidation.  
The pseudogenome expression cassettes were also found to be able to successfully express EGFP and 
luciferase (Figure 10). These EGFP and luciferase constructs could therefore successfully replace the 
commonly used mSEAP plant-made HPV pseudogenome and this could aid in keeping the cost of 
PBNAs to a minimum. Support for this is that the luciferase gene detection kit is three times cheaper 
than the SEAP detection kit and in that EGFP requires no substrate to be detected, only the fixing 
reagents and access to a fluorescent microscope or lysis buffer and western blot reagents and 
apparatus. Furthermore, EGFP and luciferase have previously been used as pseudogenomes for 
papillomavirus PsVs (Cerqueira et al., 2017, Johnson et al., 2009, Bayer et al., 2018, Touze and 
Coursaget, 1998) which allows for these new EGFP and luciferase pseudogenomes that are replicated 
in plants to be comparable to those in literature. 
However, some problems were encountered while working with the EGFP pseudogenome. The 
HEK293TT cells used in study were often clumped and overlapping in certain areas, and so were not 
ideal for visualising individual fluorescing cells and quantifying transfection or transduction efficiency 
(Figure 9). Most studies done using EGFP as pseudogenomes have used flow cytometry to quantify 
EGFP expression (Cerqueira et al., 2017, Bayer et al., 2018). However, this was not possible for this 
study due to monetary and time constraints. The EGFP expressed by the pseudogenomes in HEK293TT 
cells, can be detected and semi-quantified by western blot. Therefore, for this study western blots 
were used to analysed EGFP expression in HEK23TT cells.  
Luciferase expressed from the 7.8Kb pseudogenome construct was easily detected and quantified 
(Figure 10). Luciferase is an ideal reporter gene as the protein is the cheapest and easiest to detect; 
however, in this study, creating different sized replicons using luciferase proved difficult due to its 




pseudogenome can be cloned to make a pseudogenome of 5.3Kb, by cloning the synthesised 
mammalian expression cassette, without the EGFP, into pRIC 3.0 and then cloning the CMV-Luciferase 
fragment into pRIC.  
2.5. Conclusion 
Four pseudogenome constructs of sizes 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb were cloned. These constructs 
could replicate autonomously and continuously in plants to generate high copy numbers of 
pseudogenome replicons for L1/L2 encapsidation. These pseudogenomes also contain EGFP and 
luciferase instead of the SEAP reporter gene and therefore, could be used to decrease the cost of 
PBNAs and thereby reduce the cost of testing new neutralising antibody producing vaccines. 
Therefore, in future, these pseudogenome constructs will be used to for Agrobacterium infiltration 
into plants, wherein they will replicate and be encapsidated by L1/L2. The efficiencies at which these 
different sized replicons are encapsidated will then be determined to ascertain the optimal DNA 









The current HPV prophylactic vaccines consist of L1 VLPs that are made in either insect (Cervarix™) or 
yeast (Gardasil®) cells. However, these vaccines do not confer protection against all high-risk strains 
of HPV, such as HPV 35 which has a high prevalence in Africa (Smith et al., 2007, De Sanjose et al., 
2010), and so further vaccine development is still needed. HPV PsVs are used as challenge material, 
to study the viral life cycle, to test new neutralising antibody vaccines and are potential delivery 
vehicles for therapeutic DNA vaccines. Thus, development of an efficient, low cost and sustainable 
means of HPV PsV production would be an important step towards understanding, preventing and 
treating HPV infections and cervical cancer. 
 
3.1.1. Assembly of papillomavirus particles  
 
HPV naturally infects and replicates in terminally differentiated basal keratinocytes (Barksdale and 
Baker, 1993). These cells have been hard to maintain in cell culture and produce very low yields of 
virions which has limited the study of HPV particles and vaccine development (Conway and Meyers, 
2009, Kang et al., 2000, Meyers et al., 1992). This has led to the development of several methods to 
produce synthetic HPV particles in vitro. 
 
Various intracellular and cell-free assembly protocols were created to try and increase PV particle 
yields.  These methods were either chemical disassembly-reassembly based methods or intracellular 
methods which made use of autonomously replicating viral vectors in mammalian (Semiliki virus, 
Vaccinia virus) and insect cells (Baculovirus). While these methods were able to increase yields, they 
also led to the discovery that L2 is not needed for DNA encapsidation when assembling particles 
extracellularly (Touze and Coursaget, 1998, Zhao et al., 1998, Unckell et al., 1997, Müller et al., 1995, 
Yeager et al., 2000) but that the presence of L2 does enhance DNA encapsidation and/or infectivity of 
the particles when assembled intracellularly (Roden et al., 1996, Zhao et al., 1998, Zhou et al., 1993, 
Unckell et al., 1997, Stauffer et al., 1998).  This may be because PV particle assembly occurs in the 
nucleus, with L2 being responsible for the co-localization of all the elements required (Day et al., 1998, 
Wang and Roden, 2013). Furthermore, L2 is also known to be essential for functional PsV production 
as it has  been implicated in facilitating endosome escape (Florin et al., 2006, Richards et al., 2006), 
DNA trafficking into the nucleus (Day et al., 1998, Kondo et al., 2009, Florin et al., 2006), aiding in 




packaging in certain PV strains (Holmgren et al., 2005, Zhao et al., 1998) and enhancing infectivity of 
PsVs (Buck et al., 2008, Guan et al., 2017).  Thus, L2 is needed for efficient production of functional 
PsVs intracellularly. 
 
Additionally, in 2004, Buck et al. produced an intracellular assembly method for PV L1/L2 PsVs that 
was able to increase particle production efficiency by 10 million-fold compared to the previous Semliki 
Forest virus-derived vector methods. This protocol uses HEK293TT cells which constitutively express 
the large T-antigen, allowing for enhanced transgene DNA replication (Buck et al., 2004).  Moreover, 
this method has shown to produce approximately 109 PV transducing units/ ml and PsVs in these cells 
have further been shown to also be effective for  use in PBNAs (Pastrana et al., 2004a).  The current 
plant PsV production and purification protocols were based on this method, along with the plant HPV 
VLP protocols of Varsani et al., (2003) and Maclean et al. (2007).  
 
HPV PsV production in planta has since been performed using the L1 and L2 capsid proteins and 
pseudogenomes with the Sv40 origin of replication to ensure high levels of replication and gene 
expression when doing infectivity assays and PBNAs in HEK293TT cells.  
 
3.1.2. Papillomavirus particle purification 
While initial chemical disassembly-reassembly of PV PsVs did not generate high enough yields, these 
methods did provide insight into what conditions are needed for PV particles to assemble. These 
chemical disassembly-reassembly studies were based on those designed for polyomaviruses, like the 
Sv40, which also uses disulphide bonds for capsid assembly. These methods indicated that factors 
such as ionic strength, redox environments and pH all affect capsid assembly (Colomar et al., 1993, 
Brady et al., 1977, Mukherjee et al., 2008). Several studies have shown that PV particles require 
reducing reagents such as DTT for disassembly and that an increase in ionic strength with NaCl can 
inhibit disassembly. Therefore, in these methods, particles are disassembled with reducing agents at 
physiological ionic strength (0.15M NaCl) and then reassembled by diluting out the reducing agent 
and increasing the ionic strength to approximately 0.5M NaCl at a low pH (Mccarthy et al., 1998, Touze 
and Coursaget, 1998, Chen et al., 2001, Mukherjee et al., 2008). This indicates that particles need to 
be purified in a non-reducing, low pH environment at high salt concentrations. Moreover, all the 
studies seem to indicate that high salt concentration is important for particle assembly and several 
plant HPV VLP and PsV studies have since used 0.5M NaCl buffers for HPV particle purification (Buck 





The PV particle purification method that is most commonly used is isopycnic density gradient 
ultracentrifugation. CsCl is a common density gradient medium for purifying virus particles and has 
been used frequently for PV particle purification. Purification of PVs produced intracellularly often 
uses a sucrose cushion to remove the cell debris and pellet the sample, followed by ultracentrifugation 
on a discontinuous CsCl gradient to separate the VLPs from the PsVs (Zhou et al., 1993, Roden et al., 
1996, Stauffer et al., 1998, Unckell et al., 1997, Varsani et al., 2003, Maclean et al., 2007). However, 
the Buck et al. HEK293TT cell method was the first to make use of an iodixanol (OptiPrep™) density 
gradient to purify HPV PsVs.  The use of the OptiPrep™ medium has several advantages over CsCl 
gradients. CsCl samples need to be further purified before they can be used in animals, usually by 
chromatography, and sample is often lost here whereas OptiPep™ does not require additional steps. 
OptiPrep™ is sterile, non-ionic, non-toxic to cells and has been known to preserve the infectivity of 
the purified virus particles (Zolotukhin et al., 1999, Andersen et al., 1995). Furthermore, the 
researchers found that using OptiPrep™ actually increased the yields of PsVs compared to  VLPs after 
purification and that in contrast to CsCl the VLPs were more dense in OptiPrep™ than the PsVs (Buck 
et al., 2004). Thus, the OptiPrep™ gradient has since been used for plant PsV production (Lamprecht 
et al., 2016). 
 
In summary, purification of HPV particles that have been assembled intracellularly should ideally 
involve low pH, high salt buffers for particle formation, a sucrose cushion to remove debris and an 
OptiPrep™ density gradient to separate the empty particles from the DNA encapsidating ones.   
 
3.1.3. Production of PsVs using different sized pseudogenomes  
Various studies have shown that pseudogenomes up to 8Kb can be encapsidated by a PV VLP. 
However, while  particles were always produced with these pseudogenomes, the efficiency of DNA 
encapsidation varied with size of the pseudogenome (Stauffer et al., 1998, Touze and Coursaget, 1998, 
Zhao et al., 1998, Roden et al., 1996, Cerqueira et al., 2016, Buck et al., 2004).  A study by Zhao et al. 
indicated that BPV particles efficiently packaged a maximum of 8.8kb DNA and a study by Lamprecht 
et al. demonstrated that plant HPV PsVs can efficiently encapsidate DNA as small as 4.8Kb (Zhao et al., 
1998, Lamprecht et al., 2016).  Therefore, it should be possible to produce HPV PsVs with the 4.8Kb, 
5.8Kb, 6.8Kb, and 7.8Kb pseudogenomes used in this study. 
 
3.1.4. In planta expression of HPV Particles  
Transient expression is known to be a fast means of production HPV VLPs in plants and one that often 
results in higher yields and better immunogenicity than stable transformation.  (Varsani et al., 2006, 




production of HPV VLPs in plants using Agrobacterium-mediated transient expression. The results of 
this study demonstrated that HPV L1 yield is best when using human codon optimised L1 (pTRAc-hL1), 
achieving up to 14.9% TSP, and is even better when hL1 is targeted to the chloroplast (17% TSP, 
Maclean et al., 2007).  HPV PsVs however, cannot be made in the chloroplast and this is because the 
T-DNA of the L1/L2 genes and the pseudogenomes are transported by the A. tumefaciens virulence 
genes into the nucleus (Zupan et al., 2000) where the pseudogenomes are made into dsDNA replicons. 
If the L1/L2 proteins were chloroplast targeted, they would be post-translationally transported from 
the cytoplasm to the chloroplast (Li and Chiu, 2010) and so would not be able to encapsidate the 
pseudogenomes in the nucleus. Therefore, L1/L2 need to be targeted to the cytoplasm for transport 
into the nucleus (Day et al., 1998, Florin et al., 2002, Becker et al., 2004, Bird et al., 2008, Merle et al., 
1999, Nelson et al., 2002), to allow for encapsidation of the pseudogenome. Therefore, HPV PsVs 
should be made be in planta and should be done by transient expression using human codon 
optimised L1/L2 genes in the pTRAc, non-replicating, high copy, cytoplasm targeting vector (Figure 1).  
 
Figure 1: Diagram of the high copy number, non-replicating pTRAc vector. Cytoplasm targeted vector used for 
hL1 and hL2 expression in this study. ColE1 ori (brown), Escherichia coli origin of replication; RK2 ori (orange), 
origin of replication for Agrobacterium tumefaciens; AmpR (yellow), ampicillin ⁄ carbenicillin-resistance gene; LB 
and RB, left and right borders for T-DNA integration; SAR (purple), scaffold attachment region of the tobacco 
Rb7 gene; CaMV (green), CaMV 35S promoter with duplicated transcriptional enhancer; CHS (red), chalcone 
synthase 5’-untranslated region; 35S pA (blue), CaMV 35S polyadenylation signal. Black bar represents the T-
DNA that will be excised and transported into the plant cell nucleus by the agrobacterial vir genes. Image 






3.1.5. In planta production of HPV PsVs  
In 2016, a study by Lamprecht et al. in our group, demonstrated the successful production of HPV 16 
PsVs in N. benthamiana, using Agrobacterium-mediated expression. This study employed the various 
strategies, described above, to ensure efficient production of HPV PsVs. Firstly, the hL1 and hL2 
sequences were used in pTRAc vectors for high levels of protein expression. Next, the pseudogenome 
was cloned with the pRIC 3.0 vector (described in chapter 2.1.3) and was infiltrated at a very high 
OD600 to potentially increase the rate of encapsidation. A high salt, low pH NaOAc buffer was used for 
protein extraction as it has been shown that HPV particles form best under low  pH and high salt 
conditions (Mccarthy et al., 1998, Chen et al., 2001, Mukherjee et al., 2008) and that plant proteins, 
such as Rubisco, precipitate out of solution at ≤ pH7.4 (De Jong, 2011, Prevot-D’alvise et al., 2004). 
When purifying the particles, a two-layer sucrose density gradient of 30% and 50% was first used to 
concentrate all particles in the sample into a small 5ml 30%-layer (HPV 1.34g/mL) and to remove 
residual plant proteins from the sample before separating the particles out by iodixanol (Optiprep™) 
density gradient ultracentrifugation. Thus, using all these strategies, a protocol was devised for 
efficient HPV PsV production in planta. 
In addition, further research has been done in our lab since, using Lamprecht et al.’s protocol to 
produce HPV 18 and 35 PsVs. However, the results of these studies indicated that, while both strains 
of HPV PsVs could be produced, HPV 35 appeared to produce more regularly shaped and sized 
particles as well as higher yields of these particles (data not shown). Thus, going forward, the optimal 
DNA size for encapsidation will be determined using HPV 35 and subsequently DNA of this size will be 
used to obtain higher yields of HPV 16 and HPV 18 PsVs.  
This chapter describes the in planta production of HPV 35 PsVs using the 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb 
pseudogenomes and employing the optimised production and purification strategies described above. 
These PsVs will be used in subsequent experiments to determine the optimal DNA size for plant HPV 
PsV encapsidation.    
 
3.2. Methods 
3.2.1. Agrobacterium infiltration 
Agrobacterium tumefaciens and its vir genes and the T-DNA on its Ti plasmid, were used to transport 
the L1, L2 and pseudogenome constructs into the plant cell where it can be expressed, form particles 




3.2.1. Preparation Agrobacterial cultures 
Agrobacterium tumefaciens GV3101::pMP90RK colonies containing the human codon optimised HPV 
35 pTRAc-hL1, pTRAc-hL2 and the 4.8Kb 5.8Kb, 6.8Kb and 7.8Kb pseudogenomes were inoculated, 
separately, into 10mL of LB, containing 50μg/mL Kanamycin, 30μg/mL Rifampicin and 50μg/mL of 
Carbenicillin, and were incubated at 27˚C, for 48 hrs. Next, these cultures were inoculated into 50mL 
LBB (tryptone 2.5g/L, yeast extract 12.5g/L, NaCl 5g/L, MES 1.95g/L, pH5.6), containing the same 
antibiotics as before, and were incubated overnight at 27˚C. Thereafter, these 50mL cultures were 
inoculated into 500ml LBB supplemented with 50μg/mL kanamycin, 50μg/ml of carbenicillin and 
200μm acetosyringone and were then incubated overnight at 27˚C. The infiltration media was made 
by diluting the cultures in resuspension media, as in Lamprecht et al. (2016), and was then left to 
incubate for an hour, to allow for the stimulation of the vir genes before infiltration (Figure 2a). 
3.2.2. Infiltration of plants to make PsVs  
Four to six-week old plants, grown under 16hr light/ 8 hr dark cycles, were used for infiltration. The 
plants were pressure-infiltrated using a vacuum pump. This was done by creating a vacuum of ±100 
kPa to remove air/liquid from the leaf abaxial spaces and then releasing the vacuum to ±0 kPa to allow 
the infiltration media to fill the empty abaxial spaces (Figure 2b). Fifteen plants were infiltrated for 
each experimental and control sample.  
3.2.3. Harvesting and protein extraction 
Leaves were harvested 4 days post infiltration (dpi), homogenised in high salt NaOAc (HS-NaOAc: 0.1M 
NaOAc and 0.5M NaCl, pH 5.2) at 2x the volume (ml) of the leaf weight (mg, Figure 2c). Homogenate 
was then incubated at 4˚C for 1 hr to allow for protein extraction (Figure 2d). Thereafter, the 
homogenate was clarified using Miracloth (Sigma-Aldrich, St. Louis, USA, Figure 2e) and centrifuged 
for 20 mins at 10 000 x g at 4˚C (Figure 2f).  
3.2.4. Purification of HPV particles 
The clarified samples were loaded onto a two layered sucrose cushion. The sucrose cushion steps were 
prepared in 1x HS-NaOAc to 50% and 30%. The cushions were then spun at 17 4587 x g (Optima™ L-
100 XP centrifuge, Beckman Coulter SW32Ti rotor, Brea California) for 50 mins, after which the 30% 
fraction was removed, using a needle and syringe (Figure 2g), and dialysed overnight (Figure 2h), at 
4˚C into 1X high salt PBS (6x HS-PBS: 223.3g/L NaCl, 1.2g/L Na2HPO4, 1.44g/L KH2PO4 pH 7.4). 
An OptiPrep™ (Merck, Kenilworth, USA) density gradient was used to separate the particles. The 60% 
OptiPrep™ solution was diluted in 6x high salt PBS to make a 50% solution which was then further 
diluted with 1X HS-PBS to make the 39%, 33% and the 27% layers of the OptiPrep™ gradient. Samples 
were then ultracentrifuged at 17 4587 x g for 3.5hrs (Figure 2h). Subsequently, the gradient was 





Figure 2: Purification process of HPV PsVs and L1/L2 VLPs. a) Agrobacterial cultures were prepared to L1:L2:DNA infiltration medium and b) vacuum infiltrated into the plant. c) The 
leaves were harvested 4 dpi, homogenised in a blender with HS-NaOAc, d) incubated at 4˚C, e) filtered through Miracloth and f) clarified by centrifugation. g) Ultracentrifugation was 
used to purify and concentrate the particles into a 30% layer of a two-layered sucrose cushion. The 30% fraction was then extracted, h) dialysed into HS-PBS and ultracentrifuged on an 




3.2.5. Confirmation of L1 protein expression 
The L1 protein content in the sample fractions were analysed by western blotting. In preparation for 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), the samples were denatured 
with  1x sample application buffer (5x SAB: SDS loading 2% SDS, 100mM TrisCl pH 7.5, 2mM EDTA, 
52% glycerol, 4.3% B-mercaptoethanol) and heated for 10 minutes at 95˚C. Samples were then loaded 
in equal volume onto 10% SDS-PAGE gels and the proteins were separated, by electrophoresis, at 120V 
for ±2hrs using a Mini-PROTEAN Tetra Cell (Bio-Rad, Hercules, USA). Proteins were transferred onto 
the nitrocellulose membranes at 15V for 1.5 hrs using a Trans-blot® semi-dry transfer cell (Bio-Rad, 
Hercules, USA). Following this, the open protein binding sites on the membranes were blocked for 
30mins (Blocking buffer: 1xPBS, 5% non-fat dairy skim milk, 1% of 10%TWEEN 20) after which the 
membranes were incubated overnight at 4˚C with in-house rabbit anti-Gardasil polyclonal antisera at 
a 1:5000 dilution in blocking buffer (as determined in-house by  Dr Alta Van Zyl, BRU, University of 
Cape town, South Africa)The blots were washed 3x for 10mins in blocking buffer and incubated for 
1hr at 37˚C with goat anti-rabbit IgG alkaline phosphatase conjugated antibody (Merck, Kenilworth, 
USA) at a 1:5000 dilution in blocking buffer. Subsequently, the blots were washed 3x for 10mins using 
PBS-T and detection was carried out using the BCIP/NBT chromogenic reagent (Thermo Scientific, 
Waltham, USA). The molecular weight maker used on these blots was the Colour Protein Standard, 
Broad Range (NEB, Ipswich, USA). 
3.2.6. Confirmation of particle assembly 
Particle assembly was confirmed using transmission electron microscopy. Carbon-coated, copper grids 
were hydrophilized by glow discharging at 25mA for 30s using a Model 900 SmartSet Cold Stage 
Controller (Electron Microscopy Sciences, Montgomery County, USA). Samples were fixed onto the 
grids at a 1:5 dilution by incubating the grid on a 20μL drop of sample for 4 minutes. Following this, 
the grid was washed in 3 drops of dH2O, for 1 minute each and then negatively stained for another 
minute using 2% (w/v) Uranyl acetate.  Grids were viewed at between 27 000 – 53 000X magnification 
using a FEI Tecnai 20 electron microscope, equipped with a 200kV LaB6 emitter. Ten fields of view 
were collected for all the samples for statistical significance when counting and measuring the 
particles by eye.  
 
3.3. Results 
In planta production of HPV PsVs, using different sized pseudogenomes was investigated. The PsV and 
VLP sample gradients were fractionated into 1mL aliquots with Fraction (F) 1 corresponding to the 
50% layer of OptiPrep™, F2 the 39% layer, F3-5 the 33% layer and F6-8 the 27% layer of the OptiPrep™ 
gradient (Figure 3). The negative control was fractionated with pRIC 3.0 F1 representing the 50% layer 




gradient. Previous work showed that the 33% layer of the gradient usually contains empty HPV 
particles which have a density of 1.24g/mL in OptiPrep™ and the 27% fractions usually consists of DNA 
encapsidated particles that have a density of 1.20g/mL in OptiPrep™ (Buck et al., 2004). Thus, the 33% 
layer and 27% layers of these fractions were analysed for L1 protein expression and the L1 positive 
fractions were pooled and then examined for HPV particles that resemble 30-120nm particles found 
in previous studies on in planta production of HPV PsVs (Aves, 2016, Lamprecht et al., 2016). 
 
3.3.1. Confirmation of L1 capsid protein expression 
Samples from each fraction were analysed for protein expression by Western blot. The 55KDa L1 
protein bands were observed in the 33% and 27% OptiPrep™ fractions of all the different sized 
pseudogenome PsV samples and the VLP samples. L1 protein was found most concentrated in the 33% 
fractions and decreased in concentration as the density of the gradient decreased (Figure 3).  
Furthermore, the 50% and 39% OptiPrep™ fractions do not appear to contain L1 protein, except for in 
the 4.8Kb PsV sample which appears to contain a light 55KDa L1 protein band in the 39% fraction. 
However, this is could be due to human error while fractionating (Figure 3a). No L1 protein was 
observed in the negative control, confirming that the 55 KDa L1 bands detected in the experimental 
samples were not due to non-specific binding of the antibodies (Figure 3f). Subsequently, the sample 
fractions were pooled based on L1 concentration and density as  it is known that PV PsVs are usually 
found in the 27% layer of the OptiPrep ™ gradient and VLPs in the 33% layer of the OptiPrep ™ gradient 
(Buck et al., 2004, Bayer et al., 2018, Lamprecht et al., 2016). Thus, the F3-5 of the 33% and F6 and F7 
of the 27% fractions were pooled for all the PsV and VLP samples. These pooled samples were then 




Figure 3: Confirmation of L1 protein expression. Representative western blots of the purified PsVs and VLPs 
50%, 39%, 33% and 27% iodixanol fractions probed with the anti-Gardasil, polyclonal, primary antibody (1:5000) 
and the anti-rabbit IgG alkaline phosphatase conjugated secondary antibody (1:5000). Samples were loaded at 
equal volume (30μL) and blots were detected with BCIP for 1hr. MW, molecular weight marker; F, fraction; a), 
4.8Kb PsVs; b), 5.8Kb PsVs; c), 6.8Kb PsVs; d), 7.8Kb PsVs; e) L1/L2 VLPs; f) pRIC 3.0 empty vector control. Western 








Figure 4: Confirmation of particle assembly. Representative transmission electron microscopy images of the L1/L2 VLPs and the PsVs with different sized 
pseudogenomes. Grids were fixed with the 27% and 33% fractions of each sample, at a 1:5 dilution. The grids were then washed and negatively stained with 2% 
(w/v) uranyl acetate. White arrows, potential HPV particles; red arrows, potential L1 aggregates; blue arrows, purification artefacts. Scale bars range between 100nm 
and 200nm and samples were viewed between 27 000 - 53 000X magnification. Four out of five biological repeats were analysed for particle assembly, and ten fields 




3.3.2. Confirmation of particle assembly 
Transmission electron microscopy was used to confirm particle assembly in the 33% and 27% fractions 
of all the samples. HPV VLPs are known to have a density of 1.24g/mL in OptiPrep™. HPV PsVs are 
slightly less dense than the VLPs, with the particles appearing at the interface of, or within the 27% 
layer of the iodixanol gradient (Buck et al., 2006a, Kirnbauer et al., 1992, Bayer et al., 2018). The TEM 
results show particles in both the 33% and the 27% fractions of all the different sized pseudogenome 
PsV samples and the VLP samples, ranging in size from 30-55nm. Furthermore, the PsV and VLP 
particles were compared across biological repeats and across different sized pseudogenomes and no 
difference in size, particle distribution across the gradient or number of particles was observed (data 
not shown). Moreover, the negative control, pRIC 3.0, does not appear to contain any HPV particles, 
with only a few artefacts appearing at below 25nm (Figure 4, blue arrows). All the samples, across 
biological repeats, also appear to contain amorphous pentameric structures that resemble the L1 
aggregates shown by Varsani et al. (2006). These structures were not visible in the negative, pRIC 3.0 
control and are therefore likely to be L1 aggregates and not plant or vector induced proteins. Hence, 
the VLP and PsV samples contain 30-55nm HPV particles and some L1 aggregates.  
In summation, L1 expression was confirmed and 30-55nm HPV particles were assembled for all the 
different sized pseudogenome PsV samples and the VLP samples. No significant difference in L1 
expression or particle assembly was found between the different sized pseudogenome PsVs in both 
the 33% and 27% fractions.  
 
3.4. Discussion 
Many studies have investigated PV assembly, but many questions remain unanswered. The assembly 
of PVs is usually studied using PsVs, and by these methods, a few basics of PV assembly have been 
agreed upon. The first is that L1 is able to form VLPs on its own and encapsidate DNA on its own 
extracellularly (Touze and Coursaget, 1998, Zhao et al., 1998, Unckell et al., 1997, Müller et al., 1995, 
Yeager et al., 2000). However, studies have shown that L2 is essential for the formation of functional 
PsVs intracellularly (Roden et al., 1996, Zhao et al., 1998, Zhou et al., 1993, Unckell et al., 1997, 
Stauffer et al., 1998). More specifically, L2 is known to be necessary for HPV virion assembly as it is 
needed for efficient encapsidation in some PV types, assembly of a more stable particles and the co-
localisation of L1 and DNA in the nucleus, which allows for the assembly of PsVs.  L1 VLPs assemble 
differently to L1/L2 particles, in that L1 VLPs can form in the cytoplasm whereas L1/L2 particles are 
assembled, with the DNA and the L2, in the nucleus (Wang and Roden, 2013). Thus, for L1/L2 particles 
to be made, all elements of assembly must localise in the nucleus. L2 is the first to accumulate in the 




chaperone protein (Day et al., 1998, Florin et al., 2002, Becker et al., 2004). The L1 proteins have been 
found to assemble into capsomeres in the cytoplasm and then translocate into the nucleus with the 
help of karyopherin chaperones (Bird et al., 2008, Merle et al., 1999, Nelson et al., 2002). Moreover, 
these karyopherin proteins, along with the Hsp70 heat shock protein, have been shown to prevent 
the formation of L1 VLPs in the cytoplasm (Florin et al., 2004, Darshan et al., 2004, Bird et al., 2008). 
Once in the nucleus the L1/L2 capsid can form and bind DNA to encapsidate it (Nelson et al., 2000, 
Mallon et al., 1987, Li et al., 1997). Furthermore, these chaperone proteins are common to most 
eukaryotic cells, plants included. In fact, Hsc70 and karyopherins have been known to be part of the 
replication and assembly mechanisms of several plant viruses (Byth et al., 2001, Gorovits et al., 2013, 
Kunik et al., 1999, Gudleski et al., 2010, Sullivan and Pipas, 2001, Kennedy, 2013) and this indicates 
that these proteins could be readily available for transporting the L1 and L2 proteins into the plant 
nucleus for assembly into PsVs. However, this has yet to be confirmed and so further studies are still 
needed to test the localisation of the L1/L2 proteins in plants by either fusing them to fluorescent 
proteins or visualising the L1/L2 particles in immunogold-labelled leaf sections using TEM.  
HPV VLPs have been successfully produced in plants and in planta production of HPV PsVs has recently 
been achieved (Lamprecht et al., 2016, Kennedy, 2013). The most notable successes that have led to 
the production of the first HPV PsVs in plants was a study by Maclean et al. which showed that up to 
14.9% L1/TSP could be obtained when human-codon optimised L1 was used in the pTRAc vector 
(Maclean et al., 2007). Furthermore, another study that contributed, was that done by Regnard et al., 
using the deconstructed BeYDV viral vector, pRIC. This study illustrated the ability to replicate DNA 
constructs in plants by obtaining at least 100-fold increase in DNA, in the form of dsDNA replicons 
(Regnard et al., 2010). Finally, in 2016, the first study on HPV PsVs produced in planta was published. 
This study combined the work from Maclean et al. and Regnard et al. and illustrated that it is possible 
to make HPV PsVs in plants by expressing human codon optimised L1 and L2 from the pTRAc non -
replicating plasmids and encapsidating pseudogenome dsDNA replicons between 4.8Kb and 6.6Kb. 
Researchers were also able to show that these PsVs can be effectively used in PBNAs (Lamprecht et 
al., 2016).  
 
The data represented in this chapter confirms the first aspect of HPV PsV production in plants, L1 
capsid protein expression (Figure 3). HPV L1 protein expression patterns were found to be similar 
across all the different sized pseudogenome PsV samples as well as between the PsV and VLP samples. 
More specifically, the pattern of L1 expression obtained indicates that more L1 is present in the 33% 
fractions as opposed to the 27% fractions. This pattern of L1 accumulation was found to be consistent 




OptiPrep™ (1.24g/mL) is more likely to contain VLPs and the 27% fraction of OptiPrep™ (1.20g/mL) is 
most likely to contain PsVs (Buck et al., 2004, Bayer et al., 2018). Therefore, more protein is found in 
the putative VLP fractions as opposed to the putative PsV fractions. Overall, the results show that L1 
was expressed in all PsV and VLP samples and that the addition of DNA, of any type or size, does not 
affect L1 expression. 
 
In planta particle assembly was confirmed with TEM. Particles were formed in all the PsV and VLP 
samples, across the 33% and 27% fractions. Particle morphology resembled those of native virions and 
of other HPV PsVs previously made in planta (Lamprecht et al., 2016, Kennedy, 2013, Aves, 2016). The 
particles seen in these samples usually ranged between 30-55nm and this corresponds to that 
produced in previous HPV in planta PsV studies, with the study by Lamprecht et al. (2016), producing 
HPV 16 particles of between 30-120nm and a study done in our lab (Aves, 2016) resulting in HPV 35 
particles ranging between 35-55nm. The negative control was found to be empty and free of any L1 
protein (Figure 3f) or HPV particles, with only a few artefacts (Figure 4, blue arrows) appearing at 
≤25nm. The size of these artefacts and the fact that they do not bear resemblance to the pentameric 
structure of capsomeres ensures that they cannot be mistaken for HPV particles (Figure 4, white 
arrows) or L1 aggregates (Figure 4, red arrows). The PsV and VLP samples were also analysed for 
difference in particle size and number when using the different sized DNAs but no visible, reliable 
difference was observed (data not shown). This indicates that there is no visible marker to distinguish 
DNA encapsidating particles from empty particles, and therefore further testing would be required to 
establish this. Thus, HPV particles resembling HPV virions, found to range in size between 30-55nm, 
were observed in all the experimental and VLP samples. 
Furthermore, TEM indicated that L1 aggregates as well as particles are present in all the experimental 
samples. Varsani et al. (2006), showed that L1 aggregates can be the result of unstable or 
misassembled particles. When L2, which is required for assembly (Chen et al., 2011, Day et al., 1998, 
Ishii et al., 2005, Kirnbauer et al., 1993) was mutated, these aggregate structures formed and were  
unable to bind to conformational antibodies. Additionally, studies carried out in our lab have found 
that, while high yields of L1 protein can sometimes be obtained in plants, only a small percentage of 
these proteins form particles and even less form PsVs (personal communication with Megan 
Hendrikse, Alta Van Zyl and Renate Lamprecht, BRU, University of Cape Town, South Africa) and this 
is evident in the appearance of L1 aggregates in these samples (Figure 4). These L1 aggregates are 
seen in all the samples of all the biological repeats, suggesting that some of the particles are not 
particularly stable even though high salt, low pH, particle stabilising buffers were used (Volkin et al., 




of studies done by Cerqueira et al. These studies show that by performing disassembly-reassembly 
with HEK293H nuclear extract and ATP or by using blunt end linear pseudogenomes, HPV PsV 
expression can be increased (Cerqueira et al., 2017, Cerqueira et al., 2016). These studies were able 
to achieve efficient assembly of HPV PsVs and have reported up to 1011 infectious units/mg L1 
(Cerqueira et al., 2017) which is higher than that achieved by the Buck et al. SV40, intracellular 
assembly method which quotes 109 infectious PV units/ml (Buck et al., 2004). Furthermore, Cerqueira 
et al., also used L-glutathione oxidized (GSSG) to improve the maturation of the PsV capsids (Buck et 
al., 2005b). Papillomavirus virion maturation is redox dependent and studies have shown that the 
suprabasal layer of  Keratinocytes (terminally differentiated), that these particles naturally mature in, 
are in an oxidative state as opposed to the reductive state of the basal layer which these particles 
infect (Conway et al., 2009). GSSG is an oxidised molecule that when added to the assembly mixtures, 
creates an oxidising environment which allows for the crosslinking of the L1 disulphide bonds which 
improves the regularity and stability of the capsids and enhances DNA encapsidation and infectivity 
(Buck et al., 2005b, Cardone et al., 2014). Thus, this method, designed by Cerquiera et al., could 
potentially be optimised for use with plant made L1/L2 VLPs to reduce the amount of L1 aggregates 
and increase the number of stable PsVs being formed.  
While it can be said that L1 was expressed and particles were formed, the data presented in this 
chapter is unable indicate whether the particles are encapsidating the EGFP/Luciferase 
pseudogenome DNA. This is firstly, because only L1 expression could be confirmed and not the 
expression of L2 due to the lack of availability of an HPV 35 L2 antibody. I t is possible that L1 alone 
encapsidated DNA extracellularly to form a PsV (Touze and Coursaget, 1998, Zhao et al., 1998, Unckell 
et al., 1997, Müller et al., 1995, Yeager et al., 2000). However, L2 is known to be essential for the 
efficient production of infectious PsVs (Roden et al., 1996, Zhao et al., 1998, Zhou et al., 1993, Unckell 
et al., 1997, Stauffer et al., 1998, Wang and Roden, 2013) and therefore it is important that a 
distinction is made between the L1 only PsVs and the L1/L2 PsVs by doing infectivity assays. Secondly, 
there are no differences in the L1 accumulation patterns or particle morphology, size, number and 
distribution across the 33% and 27% OptiPrep™ densities of the PsV and VLP samples. Thus, there are 
no visual markers by which to distinguish a VLP from a PsV or by which to determine whether one 
pseudogenome size is more frequently encapsidated than another.  However, many studies have 
shown that particles can be made, using different sized pseudogenomes of any type, provided that 
they are below 8Kb in size (Stauffer et al., 1998, Touze and Coursaget, 1998, Cerqueira et al., 2016, 
Cerqueira et al., 2017, Buck et al., 2006a, Bayer et al., 2018, Zhao et al., 1998). Therefore, HPV particles 




7.8Kb. However, encapsidation and infectivity assays are still needed to confirm that these particles 
are indeed functional L1/L2 PsVs encapsidating these various sized pseudogenomes. 
3.5. Conclusion 
HPV L1 was expressed in planta and particles were formed using the 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb 
pseudogenomes. However, further downstream testing is needed to determine whether these 
particles are indeed PsVs and to determine which size pseudogenome is best for encapsidation by 





Chapter 4: Characterisation of Pseudovirions 
4.1. Introduction 
 
4.1.1.PsV infectivity:  
HPV infects epithelial cells, with different strains infecting either the cutaneous or mucosal epithelial 
tissue.   HPVs infect healthy basal keratinocytes by entering through micro-abrasions in the skin. The 
virus enters the cell through the binding of the L1  capsid protein to the HSPGs on the basement 
membrane or the basal keratinoctyes of the skin (Johnson et al., 2009, Joyce et al., 1999, Kines et al., 
2009) and this causes a conformational change in the particle, exposing the L2 protein for furin and 
proprotein convertase cleavage (Kines et al., 2009, Day et al., 2008). This in turn allows for a 
conformational change in L1 to allow it to bind to a secondary receptor on the basal keratinocytes and 
enter into the cell via endocytosis (Kines et al., 2009, Day et al., 2008, Day et al., 2010, Aksoy et al., 
2017). HPV PsVs are known to be able to specifically target cancer cells, such as melanomas and 
carcinomas, that evolve to display the form of HSPG usually only found on the basement membrane 
and basal keratinocytes of the skin (Kines et al., 2009). These traits make PV PsVs valuable assets for 
the delivery of heterologous DNA into foreign cells, specifically for targeted gene and cancer therapies.  
HPV PsVs are also important for many other applications. Culturing HPV is difficult, thus PsVs can serve 
as infectious challenge material and as a tool for monitoring the viral life cycle (Conway et al., 2009, 
Kang et al., 2000, Meyers et al., 1992, Ma et al., 2011). Furthermore, HPV PsVs are also important for 
the development of broader ranged prophylactic vaccines as they are used in PBNAs to test for 
neutralising antibodies in response to  new HPV vaccines (Pastrana et al., 2004b) and potentially for 
the production of therapeutic vaccines (Lin et al., 2010, Chabeda et al., 2018).  
4.1.2.PsV DNA encapsidation 
HPV is a dsDNA virus composed of the L1 major and the L2 minor capsid protein encapsidating a 
circular genome of up to 8Kb. The mechanisms of this DNA encapsidation have yet to be fully 
elucidated, although studies have shown that L1 and L2  both contain DNA binding sites (Li et al., 1997, 
Zhou et al., 1994, Zhao et al., 1999, Schäfer et al., 2002, Digiuseppe et al., 2017a, Fay et al., 2004) 
which play important roles in PV DNA encapsidation and gene transfer. The L1 c-terminal domain is 
known to contain an overlapping DNA-binding domain and DNA nuclear localisation signal (NLS). This 
domain has been found to be essential for efficient DNA packaging (Schäfer et al., 2002) and gene 
transfer (Touzé et al., 2000, Digiuseppe et al., 2017a), with L1 DNA binding allowing for the 
stabilisation of the PV capsid (Digiuseppe et al., 2017a). While the L2 DNA-binding site has been found 
to be insufficient for DNA encapsidation by an L1/L2 PV particle (Schäfer et al., 2002, Unckell et al., 




PV PsVs (Zhao et al., 1998, Zhou et al., 1993, Roden et al., 1996). It has also been shown that the L2 
DNA-binding site and NLS allow for the L2 mediated transfer of the DNA into the nucleus after 
endosome release (Unckell et al., 1997, Roden et al., 2001, Kawana et al., 1998) and for the 
introduction of the DNA to the assembled L1 VLP (Zhou et al., 1994). Thus, PV PsVs and virions 
produced using various expression systems, have shown that both the L1 and L2 DNA binding sites 
and NLS’s are important for PV encapsidation of DNA and gene transfer from the particle into the 
nucleus (transduction). 
While the L1 DNA binding domain is known to play a role in pseudogenome encapsidation, HPV has 
been shown to encapsidate DNA based on size rather than with the use of encapsidation signals. HPV 
PsVs were first successfully produced in 1996 (Roden et al., 1996) and by 1998, it was discovered that 
HPV does not require a DNA encapsidation signal and rather encapsidates based on size. This discovery 
was made using the intracellular assembly of PV PsVs in mammalian HEK293T cells and was later 
confirmed, by many different groups, using mammalian intracellular assembly methods (Zhao et al., 
1998, Buck et al., 2004) and extracellular disassembly-reassembly methods (Touze, 1998, Cerqueira 
et al., 2016). All these studies indicated that PV PsVs, no matter what the expression system, 
encapsidated best between 5-8Kb, with the smaller DNA resulting in the better encapsidation and/or 
transduction. These findings resulted in the HPV size discrimination theory, which was first applied in 
Buck et al. 2004 and then refined by the Cerqueira et al., in 2016. This theory states that PV PsVs are 
in constant state of disassembly and reassembly but once they encounter DNA of an appropriate size, 
below 8Kb, they form a stable particle that is resistant to disassembly. However, most of the studies 
leading up to this theory were done on non-human PVs and on either extracellularly produced PsVs 
or PsVs produced within in mammalian cells. To date, there is only one published study on the 
production of HPV PsVs in planta (Lamprecht et al., 2016). This study used two pseudogenomes of 
4.8Kb and 6.6Kb, with the results showing that a higher transduction signal was obtained when the 
4.8Kb pseudogenome was used as opposed to when the 6.6Kb pseudogenome was used. This result 
indicates that there may be a DNA size range that is optimally encapsidated by plant-made HPV PsVs 
and one way to ensure optimal plant-made HPV PsV yields, would be to ensure that the optimal size 
of pseudogenome is being used every time. Therefore, in this study, 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb 
pseudogenomes were used to make PsVs in planta and these PsVs were analysed and compared for 






4.1.3.Characterisation of HPV PsVs 
 
4.1.3.1. DNA encapsidation  
The PsVs with the 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb pseudogenome, produced in planta need to be 
characterised for frequency of pseudogenome encapsidation. Some of the early methods of testing 
for DNA encapsidation include treating the sample with benzonase nuclease and semi-quantifying 
PCRs by agarose gel densitometry (Buck et al., 2004, Touze and Coursaget, 1998, Stauffer et al., 1998), 
semi-quantifying Southern blots (Stauffer et al., 1998) and the use of pseudogenomes containing 
resistance genes, and  the quantitation thereof by transformation of E.coli (Zhao et al., 1998). One of 
the most recent methods allows for the detection of the DNA while in the particle. The virions are 
resolved on a native agarose gel strained with GelRed and Coomasie® and the encapsidated DNA band 
appears at the same position as the protein band (Masarapu et al., 2017). However, this method does 
not allow for the determination of the exact amount of DNA in the particle, the size of the DNA and 
what DNA is encapsidated in the particle. Moreover, yields of plant produced HPV PsVs are currently 
too low to be able to visualize the encapsidated DNA on an agarose gel (data not shown).  
Alternatively, plant HPV PsV studies, have used inverse PCR to determine whether the pRIC-
pseudogenome replicon was encapsidated as opposed to the full constructs (Lamprecht et al., 2016, 
Kennedy, 2013), however, this method is not quantitative. The most recent and most effective method 
currently is the use of qPCR to quantify and detect DNA purified out of the particles. PsV samples are 
treated with benzonase nuclease and then lysed with proteinase K and amplified and quantified by 
qPCR (Cerqueira et al., 2016, Cerqueira et al., 2017, Bayer et al., 2018). Thus, this current study used 
proteinase K to break open the capsids and qPCR as an accurate and efficient way to quantify 
encapsidated DNA. 
DNA to L1 ratios are used to determine the frequency of encapsidation of the DNA. L1 concentration 
provides an indication of how many PsVs there are in the sample. However, it should be noted that 
the formation of functional HPV PsVs is also dependent on L2 incorporation and so the DNA to L1 ratio 
is only an estimation of PsV concentration in the sample. However, normalising to L1 concentration 
also accounts for any batch-to-batch variation in expression and purification, as one batch of sample 
may have replicated and expressed protein better than another batch and/or have been purified 
better than another batch of sample. If there was more protein expressed in and/or extracted in one 
batch of plants compared to the other, there would most likely be more PsVs in that sample. Thus, 





4.1.3.2. Transduction efficiency 
Transduction efficiency is necessary to determine PsV functionality since DNA encapsidation does not 
necessarily equate to increased transduction (Bayer et al., 2018). Thus, the transduction efficiencies 
and the encapsidation frequencies need to be compared. Using different sized DNAs may not affect 
the structure of the particle but a study by Cerqueira et al., (2016) has indicated that when DNA close 
to or above 8Kb is used, the particle is less stable due to DNA protruding from it. Thus, DNA may be 
encapsidated, but the size of the DNA could affect the particle’s ability to infect the cell and deliver 
the DNA into the cell. So far research has shown that HPV 16 PsVs can be produced up to 1x 1011 
transducing units (Buck et al., 2004, Cerqueira et al., 2016, Cerqueira et al., 2017). However, plant 
produced HPV PsVs have yet to be fully characterised for transduction efficiency. 
HPV is known to infect basal keratinocytes, however, HEK293T and HEK293H cells have been known 
to be able to be infected by HPV PsVs (Buck et al., 2004, Stauffer et al., 1998). The mechanism of PV 
PsV infection of HEK293TT cells has yet to be fully elucidated; however, HEK293TT cells are able to act 
as an affordable, low risk model system for PsV production and testing. These cells overexpress the 
large T antigen that enhances replication of DNA by binding to its SV40 origin of replication. Therefore, 
HEK293TT cells allow for enhanced replication and expression of the PsV genes, making them useful 
for PsV expression, PBNAs and infectivity assays. Alternatives to this are NIKS ( immortalised human 
foreskin keratinocytes) which have been shown to be able to support the life cycle of several different 
types of HPVs (Allen-Hoffmann et al., 2000), thus making them a valid model for testing infectivity and 
viral replication. Other cells that can be used are primary cells, mostly W12 (Stanley et al., 1989) and 
CIN-612 (De Geest et al., 1993, Doorbar et al., 2015), which originate from infected individuals. 
However, these cells are more difficult and expensive to maintain and pose a greater health risk and 
therefore require specialised skills and facilities. Thus, HEK293TT cells will be used in this study to 
assay infectivity.  
This chapter describes the characterisation of the different sized pseudogenome PsVs by 
encapsidation and transduction efficiencies whereby the optimal size of pseudogenome for plant PsVs 
encapsidation can be determined.  
 
4.2. Methods 
4.2.1.Quantitative PCR (qPCR) sample preparation 
The PsV and VLP samples, made as described in section 3.2, were digested with proteinase K (Merck, 
Kenilworth, USA) to lyse the capsid and release the encapsidated DNA (20μl of sample, 1μl of a 1/10 




proteinase K was denatured at 95˚C for 10 mins. Dilutions of 1/1000 were then made of each sample 
for analysis by qPCR. 
4.2.2.Quantitative PCR 
An EGFP DNA standard curve was used to quantify the amount of encapsidated DNA. Standard curves 
were tested in various buffers, dH20, 1xPBS and an Optiprep™-PBS mixture (proteinase K reaction). No 
significant difference was found between the standard curves for the different buffers  and so the 
OptiPrep™ - PBS buffer was chosen (1/10 dilution of a 2:3 ratio of 33% OptiPrep™ in HS-PBS and 1xPBS) 
as it was representative of the sample conditions (Figure 1a). Five standards were used for the 
standard curve, 1ng – 0.001ng/ul (131 000 000 – 13 100 copies/rxn) of EGFP, and the samples were 
diluted to 1/1000 (Figure 1b). 
The qPCR reaction was optimised for the EGFP primers. The primers, qPCR EGFP For2: 
ACCACTACCAGCAGAACACC and qPCR EGFP Rev2: CCATGTGATCGCGCTTCTC, were designed to 
generate an amplicon of 117bp. The primers were checked theoretically for primer dimer formation 
and amplicon secondary structures using CLC workbench 6 and UMELT. Reaction mixtures were 
optimised for primer concentration, annealing temperature and elongation times (Figure 1c).  The 
final reaction mixtures used consisted of 1x LuminoCT SYBR Green qPCR Ready Mix (Merck, 
Kenilworth, USA) and 200nM of each primer. The PCR profile was as follows: 95˚C hold for 20s, 30 
cycles of annealing at 58˚C for 8s and elongation at 62˚C for 12s and a Melt analysis (72-95˚C). 
Reactions were carried out in a Rotor-Gene 3000A (QIAGEN, Venlo, Netherlands) and the data was 
analysed by Rotor-Gene 6000 Series Software 1.7 (QIAGEN, Venlo, Netherlands). 
Data was then further analysed and normalised in excel. The graphs were drawn using GraphPad 
Prism® and Mann-Whitney U non-parametric tests were used to test for significance between the PsV 
samples and a Wilcoxon test (one sample test) was used to test for significances differences between 





Figure 1: Optimisation of the standard curve and reaction conditions. a) Standard curve buffer optimisation. b) 
Standard curve analysis in 1:10 33% Optiprep+PBS buffer. R2 value of 0.99927 indicates standard curve is 
statistically accurate and the efficiency of 1 indicates 100% reaction efficiency – the DNA input matches the DNA 
predicted values. c) Melt curve analysis of standard curve and the no template control (NTC). dCt/dt, rate of 
change in the change in cycle time. 
 
4.2.3.  Protein quantification 
 
4.2.3.1. Production of L1 VLP standard curve 
An L1 VLP standard curve was used to calculate the L1 concentration in the PsV samples. The standard 
was made by producing VLPs in plants and purifying them as described in Chapter 2. Following 
Western blot analysis, L1 VLP fractions 5 (33% OptiPrep) and 6 (27% OptiPrep), were selected for 




ranging from 0.09 - 1.5 μg. Gels were stained with Coomassie Brilliant Blue ®(Merck, Kenilworth, USA) 
for an hour at 37˚C and then de-stained, first for an hour at 37˚ in de-stain solution and then overnight 
at room temperature, shaking. Gels were washed and the L1 content quantified by densitometry using 
the Syngene Gene Tools software and the L1 concentration for F5 and F6 were calculated in Excel.  
4.2.3.2. Enzyme-linked Immunosorbent Assay quantification of PsV L1 concentration  
The quantified L1 VLP fraction, was used to generate an L1 VLP Enzyme-linked Immunosorbent Assay 
(ELISA) standard curve. A five-point standard, ranging from 3.75-60ng of L1 was used. Standards and 
samples were diluted in coating buffer (10mM Tris pH 8.5) and a 100μL of each sample was added to 
an Immuno polysorb plate (ThermoFischer Scientific, Waltham, USA) and adsorbed overnight at 4˚C, 
shaking. Plates were blocked with 200μL of TBS-M (1xTBS pH7.5 and 5% non-fat dairy milk) for an hour 
at 37˚C and washed, four times, in TST-T (1xTBS p7.5, 0.05% Tween). Next, the plates were incubated 
with 100μl/well of rabbit anti-Gardasil polyclonal antisera at a 1:5000 dilution in TBS-M for 1hr at 37˚C 
and washed again, four times, with TST-T. Following this, the plate was incubated with 100μL of goat 
anti-rabbit IgG alkaline phosphatase conjugated antibody (Merck, Kenilworth, USA) at a 1:5000 
dilution in TBS-M for 1hr at 37˚C and washed with 1xTBS (pH 9.0), four times. Finally, the wells were 
incubated with 200μL of SIGMAFAST™ p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, USA) for 30 
mins in the dark and then luminescence was read at 405nm. PsVs were produced and analysed five 
times to account for variance. However, while 5 infiltration repeats were carried out, only the last two 
were purified in exactly the same way. The first three repeats were purified more dilute, with larger 
volume OptiPrep gradient layers. This resulted in low concentrations of particles and so the particles 
were concentrated for the subsequent repeats by lowering the 33% and 27% gradient layer volumes 
to 3ml instead of 5ml. This could not be done for a third repeat due to time and financial constraints. 
Data was analysed on Excel and the DNA:L1 ratios were calculated. GraphPad Prism® was used to plot 
graphs and carryout statistical analyses on the samples. A Mann-Whitney U non-parametric test was 
used to test for significance between the PsV samples and Wilcoxon test was used to test for 
significance between the PsV and the VLP samples across the two biological repeats. 
4.2.4.Infectivity assay 
HEK293TT cells were maintained as described in Section 2.2.7. Corning® Costar® TC-Treated 6 well 
plates (Sigma-Aldrich, Merck, Kenilworth, USA) were treated with 2ml of 0.1mg/ml poly-D-Lysine (10% 
(v/v) 1mg/ml Poly-D-Lysine solution  (Sigma-Aldrich, Merck, Kenilworth, USA) in 1x Gibco™ DPBS) for 
2 hours at 37˚C and dried for 1hr -1.5hrs at 37˚C. Thereafter, HEK293TT cells were seeded on coverslips 
at 150 000 cells/well. Next, 300μl of the pooled OptiPrep fractions corresponding to the 27% (fractions 
3-5) and 33% densities (fractions 6 and 7) of the purified PsVs and the VLPS were added onto the cells 




pH7.4, 150mM NaCl, 1mM MgCl2, 1% Nonidet-40 substitute and 10% glycerol). Bradford Assays were 
carried out to determine the concentration of total soluble protein (TSP) (as described in section 
2.2.8.2) and equivalent TSP was loaded onto SDS-PAGE gels. SDS-PAGE gels and Western blots were 
carried out as described in section 2.2.8.1, using a mouse anti-GFP primary antibody (Merck, 
Kenilworth, USA) at 1:1000 dilution in blocking buffer and a goat anti-mouse IgG secondary antibody 
conjugated to alkaline phosphatase (Abcam, Cambridge, UK) at 1:5000 dilution in blocking buffer. 
Differences in band intensity were detected by densitometry using the Syngene Gene Tools software. 
Five biological repeats were carried out but only the final two were purified in exactly the same way 
and so only the data of the last two repeats was used. 
 
4.3. Results 
The plant-made HPV PsVs, with 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb pseudogenomes were expressed and 
purified by Optiprep density gradient ultracentrifugation. HPV VLPs are known to have a density of 
1.24g/mL (33% OptiPrep™). HPV PsVs, however, are slightly less dense than the VLPs, with the 
particles appearing at the interface of, and within, the 27% layer of the iodixanol gradient (Buck et al., 
2006a, Kirnbauer et al., 1992, Bayer et al., 2018). The iodixanol gradients were fractionated and 
pooled as described in section 3.2.3, to obtain one 33% pooled fraction and one 27% pooled fraction 
for each PsV sample. The L1 protein concentrations were quantified by ELISA (Figure 2a) and the 
particles in the 33% and 27% pooled fractions were analysed for DNA encapsidation by qPCR (Figure 
2b). The L1 protein concentrations were used to normalise the DNA concentrations to account for 
batch-to-batch variation in expression and purification and to obtain an approximation of the 
frequencies of DNA encapsidation for each PsV sample (Figure 2c). Finally, particle infectivity was 
analysed by adding the PsVs onto HEK293TT cells and confirming DNA delivery by measuring EGFP 
expression by Western blot (Figure 3). 
4.3.1.Pseudogenome encapsidation frequencies 
The L1 concentration of the putative VLP (33% fractions) and PsV (27% fractions) containing fractions 
of the PsV samples, were quantified, by ELISA. The L1 concentrations obtained were 8-fold higher in 
the 33% PsV fractions than in the 27% PsV fractions (p=0.001). Across biological repeats, the 33% of 
the 5.8Kb PsV sample contained significantly more L1 compared to the 33% PsV fractions of the other 
PsVs.  
The PsVs, with the different sized pseudogenomes, were lysed with proteinase K and the encapsidated 
DNA released and quantified by qPCR. The DNA concentrations (Figure 2b) were normalised using the 




indication of the frequency of DNA encapsidation. These DNA: L1 ratios indicated that the PsV samples 
contained more DNA than the VLP samples, across all biological repeats, with the VLP samples 
containing 104- 106 - fold lower concentrations of DNA than the PsV samples (p=0.0002, Figure 2c). 
Moreover, a significantly higher concentration of pseudogenome DNA, approximately 100-fold, was 
found in the 27% fractions compared to the 33% fractions (p=0.001, Figure 2c). A higher concentration 
of encapsidated pseudogenome was found in the 4.8Kb (1.5 x1010 copies/ng L1) and 5.8Kb (3.2 x109 
copies/ng L1) PsVs, however this difference was not found to be significant (p=0.298).  A significant 
difference was however found between the 4.8Kb PsVs and the 6.8Kb and 7.8Kb PsVs (p=0.012) with 
the 4.8Kb PsVs containing approximately 100-fold higher concentrations of DNA.  
4.3.2. Particle infectivity  
Particle infectivity was investigated by infecting HEK293TT cells with PsVs. Cells were lysed 72 hours 
post infection and probed for EGFP expression via Western blot. Overall, the infectivity data indicated 
that EGFP was only expressed, in HEK293TT cells, after incubation with the 27% fractions and not when 
the cells were incubated with the 33% fractions. The 26kDa EGFP bands were only detected in the 27% 
samples (Figure 3b) and not in the 33% samples (Figure 3a). The data also indicated that EGFP 
expression decreased as the size of the pseudogenome increased. This is clear in that the 4.8Kb PsV 
samples produced bands 3.8 times more intense than that of the 5.8Kb PsV samples, 6.6 times more 
intense than the 6.8Kb sample and 10.8 times more intense than the 7.8Kb sample (Figure 3b). Thus, 






Figure 2: Quantification of encapsidated DNA. a) Quantification of L1 protein in the PsVs with different sized 
pseudogenome samples and the VLP control sample by ELISA. Samples were probed with rabbit anti -Gardasil 
polyclonal antisera at a 1:5000 dilution and a goat anti-rabbit IgG alkaline phosphatase conjugated secondary 
antibody at a 1:5000 dilution. b) Graph of the quantification of encapsidated DNA. Particles were broken open 
with proteinase K and quantified by qPCR using EGFP primers. c) Graph of DNA:L1 ratios, an indicator of the 
frequency  DNA encapsidation. Graphs were generated using GraphPad Prism®. Error bars represent the 
standard deviation from the mean between two biological repeats. A Mann-Whitney U non-parametric test was 
used to test for significance between the PsV samples across the last two biological repeats and Wilcoxon test 






Figure 3: Confirmation of PsV infectivity. Representative images of western blot analyses of EGFP expression 
and DNA delivery from the PsVs containing the 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb target DNAs. Two-hundred 
microlitres of the 33% (a) and 27% (b) of each of the PsVs were incubated HEK293TT cells for 4 days. Cells were 
then lysed with NP40 buffer and equal total soluble protein was loaded onto the SDS-PAGE gel. Primary 
antibody; 1:1000 anti-GFP (preabsorbed with HEK293TT cells lysate), secondary antibody, 1:5000 anti-mouse 




While HPV L1 DNA binding is essential for encapsidation, the efficiency of encapsidation still relies on 
the size of the pseudogenome being optimal. Several studies have confirmed that HPV does not 
require an encapsidation signal but rather that encapsidation efficiency is based on DNA size (Stauffer 
et al., 1998, Touze and Coursaget, 1998, Zhao et al., 1998, Roden et al., 1996, Cerqueira et al., 2016). 
The only PV type that does not fully align to this model is BPV1, as a region of its genome has been 
found to enhance the encapsidation of DNA by an L1/L2 particle (Zhao et al., 1999). Multiple studies 
have shown that extracellularly produced, mammalian, and yeast cell- produced PV PsVs encapsidate 
DNA between 5-8Kb, with the smaller pseudogenomes resulting in the better encapsidation and/or 
transduction (Stauffer et al., 1998, Touze and Coursaget, 1998, Zhao et al., 1998, Roden et al., 1996, 
Cerqueira et al., 2016, Buck et al., 2004). The smallest sized pseudogenome ever successfully 
encapsidated appears to be 4.7 Kb (De Los Pinos, 2013, Bayer et al., 2018). Although one patent does 
state that PV PsVs can encapsidate DNA as low as 2Kb, this was directly contradicted by Zhao et al., 
(1998), who show that DNA below 3.5Kb could not be encapsidated by BPV 1. The largest 
pseudogenome ever encapsidated was 8.6Kb (Zhao et al., 1998); however, most studies suggest that 
plasmids close to 8Kb in size are encapsidated less efficiently than those below 7Kb (Cerqueira et al., 
2016, Buck et al., 2004, Touze and Coursaget, 1998, Stauffer et al., 1998). Thus far studies have shown 
that DNA encapsidates most optimally around 5Kb in size, with Touze and Coursaget (1998) and Buck 
et al. (2004) indicating that 5Kb and 5.9Kb pseudogenomes, respectively, are more frequently 
encapsidated by PV particles than those above 6Kb. However, the optimal size ranges for plant-made 
PV PsVs have not yet been investigated. Therefore, this study aimed to determine the optimal 
pseudogenome size for the production of functional plant-made HPV PsVs, using pseudogenomes of 




Mammalian cell produced HPV VLPs are known to have a density of 1.24g/mL in OptiPrep™ (33%). 
HPV PsVs are slightly less dense than the VLPs, with the particles appearing at the interface of and/or 
within the 27% layer of the iodixanol gradient (Buck et al., 2006a, Kirnbauer et al., 1992, Bayer et al., 
2018). Clear differences in the amount of protein and encapsidated DNA was observed between the 
33% and 27% fractions.  L1 concentrations were approximately 8-fold higher in the 33% fractions 
compared to the 27% fractions (Figure 2a) but the corresponding DNA concentrations were 
approximately 100-fold higher in the 27% fractions compared to the 33% fractions (Figure 2b and c). 
This result was confirmed after Western blot analyses indicated that EGFP was only expressed, in 
HEK293TT cells, after incubation with the 27% fractions and not when the cells were incubated with 
the 33% fractions (Figure 3). Thus, only the particles in the 27% fractions were able to deliver DNA and 
therefore the particles found in the 27% fractions are, mostly, functional PsVs whereas those in the 
33% fractions are most likely VLPs. This result is consistent with other literature on mammalian cell 
produced HPV PsVs (Bayer et al., 2018, Lamprecht et al., 2016, Buck et al., 2004).  
Results from this study indicated that smaller pseudogenomes are more frequently encapsidated than 
larger pseudogenomes. DNA concentrations were normalised against the L1 protein concentrations 
in each fraction, to account for batch-to-batch variation in expression and purification and to give an 
indication of the frequency of DNA encapsidation. PsV samples contained significantly more DNA than 
the VLP samples, with the VLP samples containing 104- 106 - fold lower concentrations of DNA than 
the PsV samples (Figure 2b), across all biological repeats. VLPs often contain random DNA, as PV 
particles are able to encapsidate DNA, less than 8Kb, without a DNA encapsidation signal. VLPs differ 
from PsVs which contain DNA of the researcher’s choosing. Therefore, the presence of DNA signal in 
the VLP samples is most likely an artefact of the purification process, as agarose gel electrophoresis 
analyses show no EGFP expression bands and the pRIC-3.0 vector only samples contained similar levels 
DNA signal as the VLP samples (data not shown). No significant difference was found between the 
6.8Kb PsVs and the 7.8Kb PsVs. A higher concentration of encapsidated pseudogenomes was found in 
the 4.8Kb PsVs (1.5 x1010 copies/ng L1) compared to 5.8Kb PsVs (3.2 x109 copies/ng L1), however, 
statistical analyses revealed that this difference was not significant across the last two biological 
repeats, even though this difference occurred in 3 out of 4 total biological repeats.  The lack of 
significant difference between the 4.8Kb PsVs and the 5.8Kb PsVs in the last biological repeat may be 
due to the contribution of free DNA in the gradient. Note, while the data for the concentrated and 
dilute biological repeats could not be collated together, the data can still be compared separately and 
were found to follow the same trend of DNA encapsidation. Empty vector controls (data not shown) 
indicate that there is some free DNA in both the 33% and 27% OptiPrep fractions. DNase was not used 




PBS buffer. Another reason DNAse was avoided was that it may degrade DNA stuck to the outside or 
protruding from the particle, as this DNA can still be transduced although most likely not very 
efficiently. The overall encapsidated DNA concentrations for these plant-made PsVs, were found to be 
approximately 1000-fold higher than those produced in mammalian cells (2x 108 DNA copies/ng L1) 
and with cell-free assembly methods (6x 108 DNA copies/μg L1, Cerqueira et al., in 2016). This is 
unexpected as plant HPV PsV transduction is usually lower than that of mammalian PsVs (personal 
communication with Megan Hendrikse, Alta Van Zyl and Renate Lamprecht, BRU, University of Cape 
Town, South Africa). Therefore, this result may indicate that plant-made HPV PsVs do not infect 
HEK293TT cells as well as mammalian cell produced HPV PsVs. This may be because the mechanisms 
of pseudogenome encapsidation and assembly may be slightly different and/or less efficient in planta, 
possibly allowing DNA to protrude from the particle or bind to its outside.  
Although DNA encapsidation is a good indicator of a functional PsV, it is insufficient to determine PsV 
functionality. The transduction efficiency of an HPV PsV is the best indicator of its functionality. The 
data indicated that EGFP expression decreased as the size of the pseudogenome increased. This is 
clear in that the 4.8Kb PsVs produced bands 3.8 times more intense than that of the 5.8Kb PsVs, 6.6 
times more intense than the 6.8Kb PsVs and 10.8 times more intense than the 7.8Kb PsVs. 
Additionally, these data indicated that packaging of different sized DNA does not affect the infectivity 
of the PsV. This is evident in that the DNA content is highest in the 4.8Kb sample, even though this 
difference was found to be statistically insignificant, and consistently decreases as the size of the 
target DNA increases (Figure 2b,c) and that this pattern is identical to the pattern of EGFP expression 
(Figure 3b). Thus, the more DNA that was packaged, the more DNA was delivered and therefore more 
EGFP expression was obtained.  This data therefore also shows that the 4.8Kb pseudogenome, across 
all biological repeats, was able to transfer the most DNA into the HEK293TT cells. 
Altogether, the data indicates that 4.8Kb is the most optimal DNA size for HPV PsV production in 
planta. This is clear in that the DNA encapsidation as well as the transduction efficiency of these PsVs 
was much higher than that of the PsVs with larger pseudogenomes (Figure 3). There is a small and 
statistically insignificant difference in encapsidated DNA between the 4.8Kb and 5.8Kb PsVs (Figure 
2c) but a marked difference in the transduction between these two PsV samples (Figure 3b). The 
reason for this could be that a similar amount of DNA is encapsidated for both PsV samples but that 
the 4.8Kb pseudogenome is better encapsidated than the 5.8Kb pseudogenome, with less protrusion 
from the capsid and therefore less instability (Fligge et al., 2001, Cerqueira et al., 2016). Thus, this 
data suggests that the 4.8Kb pseudogenome is more frequently and possibly more stably encapsidated 
and is better transduced than other, larger pseudogenome PsVs. These results are consistent with the 




DNA, closer to 5Kb in size, encapsidate and/or transduce better than PsVs with pseudogenomes closer 
to 8Kb (Stauffer et al., 1998, Touze and Coursaget, 1998, Zhao et al., 1998, Roden et al., 1996, 
Cerqueira et al., 2016). The size of the pseudogenome currently being used for plant-made HPV PsVs 
is 4.8Kb. This data therefore validates that the size of the pseudogenome size currently being used for 
plant-made HPV PsVs produces the optimal amount functional PsVs, in terms of pseudogenome size 
(Lamprecht et al., 2016), and that size needs to be taken into consideration when designing future 
pseudogenomes for in planta production of HPV PsVs. 
This study could be taken further, by fully quantifying the encapsidation and transduction efficiencies 
of mammalian and plant-made HPV PsVs containing the 4.8Kb pseudogenomes. This comparison is 
important as this study, and others done in our lab, have shown varying yields of plant HPV PsV 
L1,encapsidated DNA and PsV to VLP ratios, compared to mammalian HPV PsVs (personal 
communication with Megan Hendrikse and Alta Van Zyl, BRU, University of Cape Town, South Africa). 
Future work could involve using alternative reporter genes and more quantitative downstream assays 
such as flow cytometry or FACS. Previous studies (personal communication with Megan Hendrikse and 
Alta Van Zyl, BRU, University of Cape Town, South Africa also show that mammalian HPV PsVs, 
generally, have a higher transduction efficiency than plant-made PsVs. Thus, there is still a need to 
properly quantify and compare mammalian HPV PsVs to plant HPV PsVs, data which could aid in 
identifying areas of HPV PsV in planta production that still require optimisation.  
Moreover, investigations into the stability of mammalian HPV PsVs compared to plant-made HPV PsVs 
could also aid in the optimisation of the in planta production of HPV PsVs. Various studies seem to 
suggest that viral particles are stabilised by encapsidation of DNA (Fligge et al., 2001, Digiuseppe et 
al., 2017a). However, research in BRU (University of Cape Town, unpublished) has shown that plant-
made HPV PsVs become non-functional after a few weeks whereas the plant-made HPV VLPs and 
mammalian HPV PsVs remain stable at -80°C for several months. Thus, the plant-made HPV PsVs may 
not keep their particle structure so their ability to infect and deliver DNA is greatly diminished with 
time. The reason for this could be that the PsVs were not efficiently assembled and thereby the DNA 
was not completely encapsidated inside the particle but is rather stuck to the outside or may be 
protruding from the plant-made HPV particle. DNA exposed on the outside of the particle would not 
be protected and is therefore open to sheering by ice crystals, after storing at low temperatures and 
freeze thawing, and to degradation over time by plant DNAses in the sample. This theory is supported 
by the TEM data obtained in section 3.3.2 which shows that plant-made HPV particles, unlike 
mammalian PsVs, are often irregular and vary in size, which could indicate that the particles have not 
assembled efficiently and therefore the pseudogenomes are not being fully encapsidated. This would 




further, in depth, comparison of encapsidation and transduction between mammalian and plant-
made HPV PsVs is necessary. To confirm this theory, a qPCR would need to be done on the same 
sample of mammalian and plant HPV PsVs, over a course of a few months, to determine differences 
in DNA degradation and therefore encapsidation efficiencies between them. Another way to 
investigate whether the mammalian and plant-made HPV PsVs may be assembling differently and/or 
with different efficiencies would be to visualise leaf sections to ensure that the particles are being 
made in the leaf and upon confirmation of this, optimise the maturation and regularity of the particles 
by adding oxidising reagents to the purification buffers (Buck et al., 2005a, Cardone et al., 2014) and 
then comparing particle formation, DNA encapsidation and transduction between mammalian and 
plant-made HPV PsVs. Therefore, the next step in plant-made PsV optimisation would be to compare 
mammalian and plant-made PsVs containing the 4.8Kb pseudogenomes’ for particle formation, DNA 
encapsidation frequency and transduction efficiency in order to highlight the areas of in planta HPV 
expression that still require optimisation. 
 
4.5. Conclusion 
In conclusion, the 4.8Kb pseudogenome was found to be more efficient for producing plant-made HPV 
PsVs compared to the 5.8Kb – 7.8Kb pseudogenomes, as the 4.8Kb pseudogenome DNA was more 
frequently encapsidated and resulted in higher transduction efficiencies. Going forward, mammalian 
and plant-made HPV PsVs, containing 4.8Kb pseudogenomes, need to be compared in order to identify 





Chapter 5: Conclusions and future work 
Cervical cancers are the second most frequent cancers in women aged 15 to 44 years (Bruni et al., 
2015b, Ferlay J, 2013). In 2018, it was estimated that 570 000 cases of cervical cancer arose globally, 
of which 311 000 were fatal (Bray et al., 2018). Studies show that HPV has the highest burden and the 
most fatalities in low income countries (Ferlay J, 2013), whereas  high income countries, such as 
Australia, are close to eradicating HPV (Bralsford and Jamieson, 2019, Bray et al., 2018, Serrano et al., 
2018, Albeck-Ripka, 2018). There are currently three L1 VLP-based prophylactic vaccines on the 
market, Gardasil™, Gardasil 9™and Cervarix®. However, these vaccines do not cover the full spectrum 
of high-risk HPVs (16, 18, 31,35,39,45,51,52,56,58,66, and 68) and do not function therapeutically. 
Thus, more research is still needed to broaden the spectrum of protection against HPV infection. 
HPV PsVs have various applications. They are used in PBNAs to test neutralising antibody responses 
of VLP vaccines and this makes them important for the testing of new prophylactic vaccines (Pastrana 
et al., 2004b). Currently, there are no therapeutic vaccines on the market. HPV PsVs are able to deliver 
DNA to cutaneious and mucosal epithelia as well as target specific  cancer cells (Kines et al., 2009, 
Kines et al., 2016) and have been shown to be able to deliver DNA into cells for targeted DNA 
vaccination and gene therapy (Graham et al., 2010, Peng et al., 2010). Thus, HPV PsVs are important 
for the development of both prophylactic and therapeutic HPV vaccines.  
Lamprecht et al. (2016) showed that HPV 16 PsVs can be produced in plants and these PsVs were 
found to function similarly to mammalian PsVs in PBNAs.  This is advantageous as plant expression 
systems are less likely to be contaminated with mammalian pathogens and are a potentially cheaper 
and more easily scalable means of PsV production (Nandi et al., 2016, Mir‐Artigues et al., 2019, 
Rybicki, 2009). The use of plant expression systems could therefore decrease the cost of testing new 
prophylactic VLP vaccines and the cost of production of HPV PsV-based therapeutic vaccines.   
Several studies have shown that PV particles encapsidate pseudogenomes between 5-8Kb, with the 
smaller sizes encapsidating better than the larger sizes (Stauffer et al., 1998, Touze and Coursaget, 
1998, Zhao et al., 1998, Roden et al., 1996, Cerqueira et al., 2016). Therefore, in order to optimise the 
amount of functional plant-made HPV PsVs obtained, this study investigated what size of 
pseudogenome is optimal for plant-made HPV PsV encapsidation.  
This study used EGFP containing pseudogenomes of 4.8Kb, 5.8Kb, 6.8Kb and 7.8Kb (Chapter 2). These 
pseudogenomes were expressed and purified (Chapter 3) and analysed for encapsidation and 
transduction efficiencies (Chapter 4). The results of this study showed that the 4.8Kb pseudogenome 
was encapsidated and transduced, by the plant-made HPV particles, more efficiently compared to all 




pseudogenomes increased. This result is consistent with literature on mammalian cell and 
extracellular produced PV PsVs (Stauffer et al., 1998, Touze and Coursaget, 1998, Zhao et al., 1998, 
Roden et al., 1996, Cerqueira et al., 2016). Thus, pseudogenome size should be considered during the 
design of a plant-made HPV PsVs. 
Future work could focus on the comparison between mammalian and plant-made HPV PsVs. This 
could allow for the identification of areas of optimization for the in planta production of HPV PsVs. 
These PsVs could also be deep sequenced to ascertain what non-target DNA’s are being encapsidated. 
Mammalian cell produced HPV PsVs are more likely to contain harmful DNA (mammalian oncogenes) 
than the plant-PsVs, as plant genes, encoding plant proteins, will most likely not affect mammalian 
cells. This could therefore provide further evidence as to whether plant PsVs are indeed a safer 
alternative to mammalian cell produced HPV PsVs.  
Future work could also focus on the optimisation of the plant-made HPV PsV purification process. The 
process could be optimised by adding a maturation step containing oxidising reagents  to improve PsV 
stability (Buck et al., 2005a, Cardone et al., 2014). Moreover, the purification process is not entirely 
sterile, as the plants are not sterile, and so contamination of the plant HPV PsV sample is always a risk.  
The likelihood of purification sterility could be increased by adding low doses of antibiotics to the 
purification buffers that will not negatively affect the downstream applications e.g. Anti-myotic/Anti-
mycotic. Following expression and purification, the next step to optimisation would be to investigate 
the particle more thoroughly. This could include testing the PsVs in PBNAs and testing infectivity in 
NIKs or primary cell lines as more relevant tests of functionality. 
HPV PsVs are a promising candidate for gene therapy and delivery of DNA vaccines. However, one 
caveat to using a high-risk strain like HPV 16 or 18 to deliver the vaccine is pre-existing immunity due 
to vaccine intake or cleared infections. Thus, alternative strains like HPV 35 could be used, although, 
this may soon form part of a broader range prophylactic vaccine. The other option is to use non-human 
HPV strains. Research by Bayer et al., (2018) shows that it is possible to make several types of non-
human PsVs in HEK293TT cells, with the Puma concolor papillomavirus-1 strain showing particular 
promise in terms of in vivo transduction efficiencies. Thus, future work could also focus on the 
production of non-human HPV PsVs in planta for possible use as DNA delivery vehicles for targeted 





Finally, this research could contribute towards cheaper testing of new HPV VLP vaccines and virus life 
cycle research, making them more affordable and accessible to low income countries. It could also 
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